```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:sssptau125rxt
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Sep 29  The Philippines Inventory of Chemicals and Chemical
                  Substances (PICCS) has been added to CHEMLIST
 NEWS  3  Oct 27  New Extraction Code PAX now available in Derwent
                  Files
 NEWS  4  Oct 27  SET ABBREVIATIONS and SET PLURALS extended in
                  Derwent World Patents Index files
 NEWS  5  Oct 27  Patent Assignee Code Dictionary now available
                  in Derwent Patent Files
 NEWS  6  Oct 27  Plasdoc Key Serials Dictionary and Echoing added to
                  Derwent Subscriber Files WPIDS and WPIX
 NEWS  7  Nov 29  Derwent announces further increase in updates for DWPI
 NEWS  8  Dec  5  French Multi-Disciplinary Database PASCAL Now on STN
 NEWS  9  Dec  5  Trademarks on STN - New DEMAS and EUMAS Files
 NEWS 10  Dec 15  2001 STN Pricing
 NEWS 11  Dec 17  Merged CEABA-VTB for chemical engineering and
                  biotechnology
 NEWS 12  Dec 17  Corrosion Abstracts on STN
 NEWS 13  Dec 17  SYNTHLINE from Prous Science now available on STN
 NEWS 14  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS 15  Jan 05  AIDSLINE is being removed from STN
 NEWS 16  Feb 06  Engineering Information Encompass files have new names
 NEWS 17  Feb 16  TOXLINE no longer being updated

 NEWS EXPRESS  FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001
```

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 11 APR 2001 HIGHEST RN 330935-94-9
DICTIONARY FILE UPDATES: 11 APR 2001 HIGHEST RN 330935-94-9

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> s neuroserpin

L1 11 NEUROSERPIN

=> d l1 11

L1 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2001 ACS
RN 179006-00-9 REGISTRY
CN Axonin 2 (chicken precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 25: PN: WO0053793 FIG: 2 unclaimed sequence
CN GenBank Z71930-derived protein GI 1359668
CN **Neuroserpin, pre- (chicken**
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s pmsf

L2 1 PMSF

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 329-98-6 REGISTRY
CN Benzenemethanesulfonyl fluoride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .alpha.-Toluenesulfonyl fluoride (7CI, 8CI)
OTHER NAMES:
CN Phenylmethanesulfonyl fluoride
CN Phenylmethylsulfonyl fluoride

CN **PMSF**
FS 3D CONCORD
MF C7 H7 F O2 S
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC, PIRA, RTECS*, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



726 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
727 REFERENCES IN FILE CAPLUS (1967 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s apmsf

L3 1 APMSF

=> s l3

L4 1 APMSF

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 71933-13-6 REGISTRY
CN Benzenemethanesulfonyl fluoride, 4-(aminoiminomethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (p-Amidinophenyl)methylsulfonyl fluoride
CN **APMSF**
CN p-Amidinophenylmethanesulfonyl fluoride
FS 3D CONCORD
MF C8 H9 F N2 O2 S
CI COM
LC STN Files: BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CSCHEM, EMBASE, MEDLINE, TOXLIT, USPATFULL



614/637

24 REFERENCES IN FILE CA (1967 TO DATE)

24 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s antipain

L5 5 ANTIPAIN

=> d l5 5

L5 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2001 ACS
RN 37682-71-6 REGISTRY
CN L-Valinamide,
N2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-L-arginyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Antipain dipicrate**
MF C27 H44 N10 O6 . 2 C6 H3 N3 O7
LC STN Files: CA, CAPLUS

CM 1

CRN 37691-11-5
CMF C27 H44 N10 O6



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s antithrombin

L6 170 ANTITHROMBIN

=> s l6 170

MISSING OPERATOR

=> d l6 170

L6 ANSWER 170 OF 170 REGISTRY COPYRIGHT 2001 ACS
RN 9000-94-6 REGISTRY
CN **Antithrombin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **Antithrombin III**
CN Heparin cofactor
CN Heparin cofactor B
CN Org 10849
CN Thrombin inhibitor
AR 90170-80-2
DR 9041-91-2, 52014-67-2
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NIOSHTIC, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
4265 REFERENCES IN FILE CA (1967 TO DATE)
471 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4278 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s leupeptin

L7 11 LEUPEPTIN

=> d l7 1

L7 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2001 ACS
RN 81458-06-2 REGISTRY
CN **Peptidase, leupeptin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **Leupeptin peptidase**
CN **Leupeptin-inactivating enzyme**
MF Unspecified
CI MAN
LC STN Files: BIOSIS, CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d l78\

'L78\' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats

are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):bib

'BIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used

SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):abs

'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):

ENTER DISPLAY FORMAT (IDE):

ENTER DISPLAY FORMAT (IDE):ide

L7 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2001 ACS
RN 81458-06-2 REGISTRY
CN **Peptidase, leupeptin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **Leupeptin peptidase**
CN **Leupeptin-inactivating enzyme**
MF Unspecified
CI MAN
LC STN Files: BIOSIS, CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1 11 S NEUROSERPIN
L2 1 S PMSF
L3 1 S APMSF
L4 1 S L3

```
L5            5 S ANTIPAIN
L6          170 S ANTITHROMBIN
L7           11 S LEUPEPTIN

=> d l7 11


L7   ANSWER 11 OF 11  REGISTRY  COPYRIGHT 2001 ACS
RN   24125-15-3  REGISTRY
CN   Valeramide, N-(1-formyl-4-guanidinobutyl)-4-methyl-2-(4-methyl-2-
     propionamidovaleramido)-, monohydrochloride, stereoisomer (8CI)  (CA
INDEX
     NAME)
OTHER CA INDEX NAMES:
CN   Argininal, N2-[N-(N-propionyl-L-leucyl)-L-leucyl]-, monohydrochloride,
DL-
     (8CI)
OTHER NAMES:
CN   Leupeptin propyl-LL hydrochloride
FS   STEREOSEARCH
DR   36794-11-3
MF   C21 H40 N6 O4 . Cl H
LC   STN Files:   CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXLIT, USPATFULL
CRN  (24365-46-6)

Absolute stereochemistry.
```



● HCl

```
4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> d dichlorocoumarin

'DICHLOROCOUMARIN' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
```

SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):ide

L7 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2001 ACS
RN 81458-06-2 REGISTRY
CN **Peptidase, leupeptin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **Leupeptin peptidase**
CN **Leupeptin-inactivating enzyme**
MF Unspecified
CI MAN
LC STN Files: BIOSIS, CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s dichlorocoumarin

L8 9 DICHLOROCOUMARIN

=> d l8 709

9 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):7-9

L8 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2001 ACS
RN 36051-82-8 REGISTRY
CN 2H-1-Benzopyran-2-one, 6,8-dichloro-4-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Coumarin, 6,8-dichloro-4-hydroxy- (7CI)
OTHER NAMES:
CN **4-Hydroxy-6,8-dichlorocoumarin**
CN 6,8-Dichloro-4-hydroxycoumarin
FS 3D CONCORD
MF C9 H4 Cl2 O3
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS
(*File contains numerically searchable property data)



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L8 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2001 ACS
RN 20882-68-2 REGISTRY
CN 2H-1-Benzopyran-2-one, 3,6-dichloro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Coumarin, 3,6-dichloro- (7CI, 8CI)
OTHER NAMES:
CN **3,6-Dichlorocoumarin**
FS 3D CONCORD
MF C9 H4 Cl2 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L8 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2001 ACS
RN 2199-91-9 REGISTRY
CN 2H-1-Benzopyran-2-one, 3-acetyl-6,8-dichloro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Coumarin, 3-acetyl-6,8-dichloro- (6CI, 7CI, 8CI)
OTHER NAMES:
CN **3-Acetyl-6,8-dichlorocoumarin**
FS 3D CONCORD
MF C11 H6 Cl2 O3
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM
(*File contains numerically searchable property data)



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s tlck

L9 2 TLCK

=> d l9 1-2

L9 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN 23877-38-5 REGISTRY
CN Benzenesulfonamide, N-[(1S)-1-(chloroacetyl)-3-methylbutyl]-4-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, N-[1-(chloroacetyl)-3-methylbutyl]-4-methyl-, (S)-
CN p-Toluenesulfonamide, N-[1-(chloroacetyl)-3-methylbutyl]-, stereoisomer (8CI)
OTHER NAMES:
CN L-1-Tosylamide-2-leucyl chloromethyl ketone
CN **TLCK**
CN Tosyl-L-leucyl chloromethyl ketone
FS STEREOSEARCH
MF C14 H20 Cl N O3 S
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



9 REFERENCES IN FILE CA (1967 TO DATE)
9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L9 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN 2364-87-6 REGISTRY

CN Benzenesulfonamide, N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methyl-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, N-[5-amino-1-(chloroacetyl)pentyl]-4-methyl-, (S)-
CN p-Toluenesulfonamide, N-[5-amino-1-(chloroacetyl)pentyl]-, L- (8CI)
OTHER NAMES:
CN .alpha.-N-(p-Tosyl)-L-lysyl chloromethyl ketone
CN 1-Chloro-3-tosylamido-7-amino-L-2-heptanone
CN L-1-Chloro-3-tosylamido-7-amino-2-heptanone
CN N-.alpha.-p-Tosyl-L-lysine chloromethylketone
CN N-.alpha.-Tosyl-L-lysyl-chloromethyl ketone
CN N-Tosyl-L-lysine chloromethyl ketone
CN N-Tosyl-L-lysyl chloromethyl ketone
CN N.alpha.-p-Tosyl-L-lysine chloromethyl ketone
CN N.alpha.-p-Tosyl-L-lysylchloromethyl ketone
CN N.alpha.-Tosyl-L-lysine chloromethyl ketone
CN N.alpha.-Tosyl-L-lysyl chloromethyl ketone
CN **TLCK**
CN Tosyl-L-lysine chloromethyl ketone
CN Tosyllysine chloromethyl ketone
CN Tosyllysyl chloromethyl ketone
FS STEREOSEARCH
DR 130021-39-5, 3414-37-7
MF C14 H21 Cl N2 O3 S
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CSCHEM, DDFU, DRUGU, EMBASE, NIOSHTIC, RTECS*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



364 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
365 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.68	57.83

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 11 APR 2001 HIGHEST RN 330935-94-9
DICTIONARY FILE UPDATES: 11 APR 2001 HIGHEST RN 330935-94-9

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001

```
L1          11 S NEUROSERPIN
L2           1 S PMSF
L3           1 S APMSF
L4           1 S L3
L5           5 S ANTIPAIN
L6         170 S ANTITHROMBIN
L7          11 S LEUPEPTIN
L8           9 S DICHLOROCOUMARIN
L9           2 S TLCK
```

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.62	58.45

FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 5 Apr 2001 VOL 134 ISS 16
FILE LAST UPDATED: 5 Apr 2001 (20010405/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CA on STN.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying,

```
=> s l1

L10         17 L1

=> e neuroserpin

E1           1     NEUROSERCRETING/BI
E2           1     NEUROSERETORY/BI
E3          17 --> NEUROSERPIN/BI
E4           2     NEUROSERPINS/BI
E5          67     NEUROSES/BI
E6           3     NEUROSHELL/BI
E7           2     NEUROSIGNAL/BI
E8           2     NEUROSIGNALLING/BI
E9          10     NEUROSIN/BI
E10        371     NEUROSIS/BI
E11          1     NEUROSISLIKE/BI
E12          1     NEUROSKELETAL/BI

=> s l2

L11        728 L2

=> s l3

L12         24 L3

=> s l5

L13        343 L5

=> s l6

L14       4326 L6

=> s l7

L15        171 L7

=> s l8

L16         16 L8

=> s l9

L17        372 L9

=> e neuropathy

E1           3     NEUROPATHWAY/BI
E2           6     NEUROPATHWAYS/BI
E3        5490 --> NEUROPATHY/BI
E4           1     NEUROPATHYS/BI
E5           1     NEUROPATTERNING/BI
E6           1     NEUROPATTHY/BI
E7           1     NEUROPDPTIDE/BI
E8           2     NEUROPEDIATRIC/BI
E9           3     NEUROPEDIATRICS/BI
E10          1     NEUROPEITHELIUM/BI
E11          1     NEUROPELAGIC/BI
```

```
E12          3     NEUROPENIA/BI

=> s e3

L18       5490 NEUROPATHY/BI

=> e epilepsy

E1           3     EPILEPSIS/BI
E2           1     EPILEPSRY/BI
E3        8845 --> EPILEPSY/BI
E4           1     EPILEPSYE/BI
E5           1     EPILEPTGENIC/BI
E6           1     EPILEPTI/BI
E7        3510     EPILEPTIC/BI
E8           4     EPILEPTICAL/BI
E9         237     EPILEPTICS/BI
E10        696     EPILEPTICUS/BI
E11          1     EPILEPTICY/BI
E12       1392     EPILEPTIFORM/BI

=> s e3-e12

          8845 EPILEPSY/BI
             1 EPILEPSYE/BI
             1 EPILEPTGENIC/BI
             1 EPILEPTI/BI
          3510 EPILEPTIC/BI
             4 EPILEPTICAL/BI
           237 EPILEPTICS/BI
           696 EPILEPTICUS/BI
             1 EPILEPTICY/BI
          1392 EPILEPTIFORM/BI
L19      10805 (EPILEPSY/BI OR EPILEPSYE/BI OR EPILEPTGENIC/BI OR EPILEPTI/BI
               OR EPILEPTIC/BI OR EPILEPTICAL/BI OR EPILEPTICS/BI OR
EPILEPTICU
               S/BI OR EPILEPTICY/BI OR EPILEPTIFORM/BI)

=> e seizure

E1           1     SEIZUORGENIC/BI
E2           3     SEIZURAL/BI
E3        9693 --> SEIZURE/BI
E4           9     SEIZURED/BI
E5           8     SEIZURELIKE/BI
E6       10034     SEIZURES/BI
E7           2     SEIZURGENIC/BI
E8          11     SEIZURING/BI
E9           4     SEIZUROGENIC/BI
E10          1     SEIZURS/BI
E11         19     SEJ/BI
E12          1     SEJANUS/BI

=> s e3-e6

          9693 SEIZURE/BI
             9 SEIZURED/BI
             8 SEIZURELIKE/BI
         10034 SEIZURES/BI
L20      14562 (SEIZURE/BI OR SEIZURED/BI OR SEIZURELIKE/BI OR SEIZURES/BI)

=> e hypoxia
```

```
E1            1     HYPOXENOLITHS/BI
E2            3     HYPOXI/BI
E3        24801 --> HYPOXIA/BI
E4            1     HYPOXIAIGNIFICANTLY/BI
E5            1     HYPOXIAIN/BI
E6            1     HYPOXIAINDUCED/BI
E7            1     HYPOXIAISCHEMIA/BI
E8            2     HYPOXIAL/BI
E9            1     HYPOXIAM/BI
E10           1     HYPOXIANORMOXIA/BI
E11           1     HYPOXIAPNITRIC/BI
E12          17     HYPOXIAS/BI

=> s e3

L21       24801 HYPOXIA/BI

=> e stroke

E1            3     STROKAN/BI
E2            1     STROKAR/BI
E3        11880 --> STROKE/BI
E4            1     STROKE1/BI
E5            1     STROKECYCLE/BI
E6           31     STROKED/BI
E7           16     STROKELIKE/BI
E8            6     STROKEPRONE/BI
E9            3     STROKER/BI
E10         895     STROKES/BI
E11           1     STROKESTOWN/BI
E12           1     STROKILACEUM/BI

=> s e3

L22       11880 STROKE/BI

=> s l17 and l18

L23           0 L17 AND L18

=> s l17 and l19

L24           0 L17 AND L19

=> s l17 and l20

L25           0 L17 AND L20

=> s l17 and l21

L26           0 L17 AND L21

=> s l17 and l22

L27           0 L17 AND L22

=> s l16 and l18

L28           0 L16 AND L18

=> s l18 or l19 or l20

L29       25960 L18 OR L19 OR L20
```

=> s l29 and l16

L30 0 L29 AND L16

=> s l29 and l15

L31 0 L29 AND L15

=> s l29 and l14

L32 4 L29 AND L14

=> d l32 1-4

L32 ANSWER 1 OF 4 CA COPYRIGHT 2001 ACS
AN 133:320515 CA
TI Clinical and biochemical characteristics of congenital disorder of glycosylation type Ic, the first recognized endoplasmic reticulum defect in N-glycan synthesis
AU Grunewald, S.; Imbach, T.; Huijben, K.; Rubio-Gozalbo, M. E.; Verrips, A.;
De Klerk, J. B. C.; Stroink, H.; De Rijk-Van Andel, J. F.; Van Hove, J. L.
K.; Wendel, U.; Matthijs, G.; Hennet, T.; Jaeken, J.; Wevers, R. A.
CS Department of Pediatrics, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany
SO Ann. Neurol. (2000), 47(6), 776-781
CODEN: ANNED3; ISSN: 0364-5134
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 29
RE
(3) Burda, P; J Clin Invest 1998, V102, P647 CA
(5) de Koning, T; Biochem Biophys Res Commun 1998, V245, P38 CA
(7) Grunewald, S; Biochem Biophys Acta 1999, V1455, P54 CA
(9) Imbach, T; Proc Natl Acad Sci USA 1999, V96, P6982 CA
(11) Jaeken, J; Am J Hum Genet 1998, V62, P1535 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 4 CA COPYRIGHT 2001 ACS
AN 133:15850 CA
TI Cerebral venous sinus thrombosis associated with hepatic cirrhosis
AU Singhal, A. B.; Buonanno, F.; Rordorf, G.
CS Department of Neurology, VBK 802, Massachusetts General Hospital, Boston, MA, USA
SO J. Neurol. Sci. (1999), 171(1), 65-68
CODEN: JNSCAG; ISSN: 0022-510X
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 10
RE
(1) Boita, F; Sem Hosp Paris 1979, V55(9-10), P499 MEDLINE
(3) Daif, A; Stroke 1995, V26(7), P1193 MEDLINE
(4) Harper, P; Lancet 1988, V2(8617), P924 MEDLINE
(5) Hauser, D; Am J Ophthalmol 1996, V122(4), P592 MEDLINE
(6) Iranzo, A; J Neurol Neurosurg Psychiatry 1998, V64, P688 MEDLINE
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 3 OF 4 CA COPYRIGHT 2001 ACS

AN 132:263637 CA
TI Abnormalities in thrombin-antithrombin pathway in AL amyloidosis
AU Gamba, Gabriella; Montani, Nadia; Anesi, Ernesto; Palladini, Giovanni; Lorenzutti, Federica; Perfetti, Vittorio; Merlini, Giampaolo
CS Department of Internal Medicine, University of Pavia, IRCCS Policlinico San Matteo, Pavia, 27100, Italy
SO Amyloid (1999), 6(4), 273-277
CODEN: AIJIET; ISSN: 1350-6129
PB Parthenon Publishing Group
DT Journal
LA English
RE.CNT 25
RE
(10) Husby, G; Clin Immunol Immunopathol 1994, V70, P2 CA
(13) Khoory, M; J Clin Invest 1980, V65, P666 CA
(17) Marcatti, M; Thromb Res 1995, V80, P333 CA
(19) Merlini, G; Clin Chem 1981, V27, P1862 CA
(22) Sas, G; Thrombos Res 1975, V6, P87 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
AN 121:149109 CA
TI Treatment of neurodegenerative diseases with thrombin inhibitors
IN Friedrich, Thomas
PA BASF A.-G., Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4303646	A1	19940811	DE 1993-4303646	19930209
	WO 9417821	A1	19940818	WO 1994-EP259	19940129
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2153420	AA	19940818	CA 1994-2153420	19940129
	EP 683674	A1	19951129	EP 1994-906174	19940129
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	JP 08507047	T2	19960730	JP 1994-517604	19940129
PRAI	DE 1993-4303646	19930209			
	WO 1994-EP259	19940129			

=> d 132 4 all

L32 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
AN 121:149109 CA
TI Treatment of neurodegenerative diseases with thrombin inhibitors
IN Friedrich, Thomas
PA BASF A.-G., Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K037-02
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4303646	A1	19940811	DE 1993-4303646	19930209
	WO 9417821	A1	19940818	WO 1994-EP259	19940129

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2153420 AA 19940818 CA 1994-2153420 19940129
EP 683674 A1 19951129 EP 1994-906174 19940129
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE
JP 08507047 T2 19960730 JP 1994-517604 19940129
PRAI DE 1993-4303646 19930209
WO 1994-EP259 19940129
AB Thrombin inhibitors, which may be combined with NGF, are useful in prepn. of medicaments for treatment of neurodegenerative diseases and disorders resulting e.g. from HIV-induced **neuropathy**, ischemia, subarachnoid hemorrhage, stroke, Alzheimer's disease, Huntington's disease, and parkinsonism. Thus, intracerebroventricular infusion of hirudin or protease nexin-1 (1-100 .mu.g/kg) into rats with unilateral brain lesions improved memory performance and the no. of choline acetyltransferase-pos. cortical neurons compared to those in operated but sham-treated rats.
ST nerve degeneration treatment thrombin inhibitor; hirudin nerve degeneration treatment; proteinase nexin nerve degeneration treatment
IT Memory, biological
(after brain lesion, thrombin inhibitor effect on)
IT Brain
(regeneration of, after lesion, thrombin inhibitor effect on)
IT Nerve, disease
(degeneration, treatment of, with thrombin inhibitors)
IT Brain, disease
(lesion, nerve regeneration after, thrombin inhibitor effect on)
IT 8001-27-2, Hirudin **9000-94-6**, Antithrombin 148196-69-4
RL: BIOL (Biological study)
(nerve degeneration treatment with)
IT 9061-61-4, Nerve growth factor
RL: BIOL (Biological study)
(nerve degeneration treatment with thrombin inhibitor and)

=> s l29 and l13

L33 0 L29 AND L13

=> s l29 and l12

L34 0 L29 AND L12

=> s l29 and l11

L35 30 L29 AND L11

=> d l35 15-30

L35 ANSWER 15 OF 30 CA COPYRIGHT 2001 ACS
AN 119:220257 CA
TI Properties of partly preinhibited hen brain **neuropathy** target esterase
AU Vicedo, J. L.; Carrera, V.; Barril, J.; Vilanova, E.
CS Dep. Neurochem., Alicante Univ., Alicante, Spain
SO Chem.-Biol. Interact. (1993), 87(1-3), 417-23
CODEN: CBINA8; ISSN: 0009-2797
DT Journal
LA English

L35 ANSWER 16 OF 30 CA COPYRIGHT 2001 ACS
AN 119:153659 CA

TI Prophylaxis against and promotion of organophosphate-induced delayed **neuropathy** by phenyl di-n-pentylphosphinate
AU Johnson, M. K.; Read, D. J.
CS MRC Toxicol. Unit, Univ. Leicester, Leicester, LE1 9HN, UK
SO Chem.-Biol. Interact. (1993), 87(1-3), 449-55
CODEN: CBINA8; ISSN: 0009-2797
DT Journal
LA English

L35 ANSWER 17 OF 30 CA COPYRIGHT 2001 ACS
AN 118:53794 CA
TI Local application of neuropathic organophosphorus compounds to hen sciatic
nerve: inhibition of **neuropathy** target esterase and peripheral neurological impairments
AU Carrera, Victoria; Barril, Jose; Mauricio, Maricruz; Pellin, Maricruz; Vilanova, Eugenio
CS Dep. Neurochem., Univ. Alicante, Alicante, 03002, Spain
SO Toxicol. Appl. Pharmacol. (1992), 117(2), 218-25
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 18 OF 30 CA COPYRIGHT 2001 ACS
AN 118:34045 CA
TI Phenylmethanesulfonyl fluoride elicits and intensifies the clinical expression of neuropathic insults
AU Moretto, A.; Bertolazzi, M.; Capodicasa, E.; Peraica, M.; Richardson, R. J.; Scapellato, M. L.; Lotti, M.
CS Ist. Med. Lavoro, Univ. Stud. Padova, Padua, I-35127, Italy
SO Arch. Toxicol. (1992), 66(1), 67-72
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English

L35 ANSWER 19 OF 30 CA COPYRIGHT 2001 ACS
AN 118:2118 CA
TI Clinical expression of organophosphate-induced delayed polyneuropathy in rats
AU Moretto, Angelo; Capodicasa, Eugenio; Lotti, Marcello
CS Ist. Med. Lavoro, Univ. Padova, Padua, 35127, Italy
SO Toxicol. Lett. (1992), 63(1), 97-102
CODEN: TOLED5; ISSN: 0378-4274
DT Journal
LA English

L35 ANSWER 20 OF 30 CA COPYRIGHT 2001 ACS
AN 117:165625 CA
TI The inhibitory effect of neuropathic organophosphate esters on neurite outgrowth in cell cultures: a basis for screening for delayed neurotoxicity
AU Henschler, D.; Schmuck, G.; Van Aerssen, M.; Schiffmann, D.
CS Inst. Toxicol., Univ. Wuerzburg, Wuerzburg, D-8700, Germany
SO Toxicol. in Vitro (1992), 6(4), 327-35
CODEN: TIVIEQ; ISSN: 0887-2333
DT Journal
LA English

L35 ANSWER 21 OF 30 CA COPYRIGHT 2001 ACS
AN 115:176927 CA
TI Promotion of organophosphates induced delayed polyneuropathy by phenylmethanesulfonyl fluoride. Comments
AU Pope, Carey N.; Padilla, Stephanie

CS Sch. Pharm., Northeast Louisiana Univ., Monroe, LA, 71209, USA
SO Toxicol. Appl. Pharmacol. (1991), 110(1), 179-80
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 22 OF 30 CA COPYRIGHT 2001 ACS
AN 115:43729 CA
TI Promotion of organophosphate-induced delayed polyneuropathy by phenylmethanesulfonyl fluoride
AU Lotti, Marcello; Caroldi, Stefano; Capodicasa, Eugenio; Moretto, Angelo
CS Ist. Med. Lav., Univ. Padova, Padua, I-35127, Italy
SO Toxicol. Appl. Pharmacol. (1991), 108(2), 234-41
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 23 OF 30 CA COPYRIGHT 2001 ACS
AN 110:149296 CA
TI Triphenyl phosphite neurotoxicity in the hen: inhibition of neurotoxic esterase and of prophylaxis by phenylmethylsulfonyl fluoride
AU Carrington, Clark D.; Abou-Donia, Mohamed B.
CS Med. Cent., Duke Univ., Durham, NC, 27710, USA
SO Arch. Toxicol. (1988), 62(5), 375-80
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English

L35 ANSWER 24 OF 30 CA COPYRIGHT 2001 ACS
AN 106:190736 CA
TI Central-peripheral delayed **neuropathy** caused by diisopropyl phosphorofluoridate (DFP): segregation of peripheral nerve and spinal cord
effects using biochemical, clinical, and morphological criteria
AU Lotti, M.; Caroldi, S.; Moretto, A.; Johnson, M. K.; Fish, C. J.; Gopinath, C.; Roberts, N. L.
CS Ist. Med. Lavoro, Univ. Padova, Padua, 35127, Italy
SO Toxicol. Appl. Pharmacol. (1987), 88(1), 87-96
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 25 OF 30 CA COPYRIGHT 2001 ACS
AN 104:16305 CA
TI Phenylmethylsulfonyl fluoride protects rats from mipafox-induced delayed **neuropathy**
AU Veronesi, Bellina; Padilla, Stephanie
CS Health Effects Res. Lab., U. S. Environ. Prot. Agency, Research Triangle Park, NC, 27711, USA
SO Toxicol. Appl. Pharmacol. (1985), 81(2), 258-64
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 26 OF 30 CA COPYRIGHT 2001 ACS
AN 102:107664 CA
TI Neurotoxic esterase in rooster testis
AU Lotti, Marcello; Wei, Eddie T.; Spear, Robert C.; Becker, Charles E.
CS North. California Occup. Health Cent., Univ. California, San Francisco, CA, USA
SO Toxicol. Appl. Pharmacol. (1985), 77(1), 175-80
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal

LA English

L35 ANSWER 27 OF 30 CA COPYRIGHT 2001 ACS
AN 102:1635 CA
TI Intraarterial injection of diisopropylfluorophosphate or phenylmethanesulfonyl fluoride produces unilateral **neuropathy** or protection, respectively, in hens
AU Caroldi, Stefano; Lotti, Marcello; Masutti, Alberto
CS Ist. Med. Lavoro, Univ. Padova, Padua, 35127, Italy
SO Biochem. Pharmacol. (1984), 33(20), 3213-17
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L35 ANSWER 28 OF 30 CA COPYRIGHT 2001 ACS
AN 99:207626 CA
TI An electrophysiologic and ultrastructural study of the phenylmethanesulfonyl fluoride protection against a delayed organophosphorus **neuropathy**
AU Drakontides, Anna B.; Baker, Thomas
CS Dep. Anat., New York Med. Coll., Valhalla, NY, 10595, USA
SO Toxicol. Appl. Pharmacol. (1983), 70(3), 411-22
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 29 OF 30 CA COPYRIGHT 2001 ACS
AN 94:97371 CA
TI The effects of phenylmethanesulfonyl fluoride on delayed organophosphorus **neuropathy**
AU Baker, Thomas; Lowndes, Herbert E.; Johnson, Martin K.; Sandborg, Irene C.
CS Med. Coll., Cornell Univ., New York, NY, 10021, USA
SO Arch. Toxicol. (1980), 46(3-4), 305-11
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English

L35 ANSWER 30 OF 30 CA COPYRIGHT 2001 ACS
AN 91:69597 CA
TI Neurotoxicity of organophosphorus pesticides: predictions can be based on in vitro studies with hen and human enzymes
AU Lotti, Marcello; Johnson, Martin Keith
CS Mol. Toxicol. Sect., MRC, Carshalton/Surrey, SM5 4EF, Engl.
SO Arch. Toxicol. (1978), 41(3), 215-21
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1 11 S NEUROSERPIN
L2 1 S PMSF
L3 1 S APMSF
L4 1 S L3
L5 5 S ANTIPAIN
L6 170 S ANTITHROMBIN

```
L7            11 S LEUPEPTIN
L8             9 S DICHLOROCOUMARIN
L9             2 S TLCK

     FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

     FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10           17 S L1
                 E NEUROSERPIN
L11          728 S L2
L12           24 S L3
L13          343 S L5
L14         4326 S L6
L15          171 S L7
L16           16 S L8
L17          372 S L9
                 E NEUROPATHY
L18         5490 S E3
                 E EPILEPSY
L19        10805 S E3-E12
                 E SEIZURE
L20        14562 S E3-E6
                 E HYPOXIA
L21        24801 S E3
                 E STROKE
L22        11880 S E3
L23            0 S L17 AND L18
L24            0 S L17 AND L19
L25            0 S L17 AND L20
L26            0 S L17 AND L21
L27            0 S L17 AND L22
L28            0 S L16 AND L18
L29        25960 S L18 OR L19 OR L20
L30            0 S L29 AND L16
L31            0 S L29 AND L15
L32            4 S L29 AND L14
L33            0 S L29 AND L13
L34            0 S L29 AND L12
L35           30 S L29 AND L11

=> d 135 7-14


L35  ANSWER 7 OF 30  CA  COPYRIGHT 2001 ACS
AN   127:216150  CA
TI   Phenyl valerate esterases other than neuropathy target esterase
     and the promotion of organophosphate polyneuropathy
AU   Milatovic, Dejan; Moretto, Angelo; Osman, Khaled A.; Lotti, Marcello
CS   Istituto di Medicina del Lavoro, Universita degli Studi di Padova, Padua,
     I-35127, Italy
SO   Chem. Res. Toxicol. (1997), 10(9), 1045-1048
     CODEN: CRTOEC; ISSN: 0893-228X
PB   American Chemical Society
DT   Journal
LA   English

L35  ANSWER 8 OF 30  CA  COPYRIGHT 2001 ACS
AN   127:215998  CA
TI   Improved in vitro method for screening organophosphate-induced delayed
     polyneuropathy
AU   Schmuck, G.; Ahr, H. J.
CS   Bayer AG, Pharma Research Centre, Wuppertal, D-42096, Germany
SO   Toxicol. in Vitro (1997), 11(3), 263-270
```

CODEN: TIVIEQ; ISSN: 0887-2333
PB Elsevier
DT Journal
LA English

L35 ANSWER 9 OF 30 CA COPYRIGHT 2001 ACS
AN 125:294975 CA
TI Sulfonyl fluorides and the promotion of diisopropyl fluorophosphate **neuropathy**
AU Osman, Khaled A.; Moretto, Angelo; Lotti, Marcello
CS Instituto di Medicina del Lavoro, Universita degli Studi di Padova, Padua, 35127, Italy
SO Fundam. Appl. Toxicol. (1996), 33(2), 294-297
CODEN: FAATDF; ISSN: 0272-0590
DT Journal
LA English

L35 ANSWER 10 OF 30 CA COPYRIGHT 2001 ACS
AN 125:134966 CA
TI Subacute neurotoxicity induced in mice by potent organophosphorus **neuropathy** target esterase inhibitors
AU Wu, Shao-Yong; Casida, John E.
CS Environmental Chemistry and Toxicology Lab., Univ. of California, Berkeley, CA, 94720-3112, USA
SO Toxicol. Appl. Pharmacol. (1996), 139(1), 195-202
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L35 ANSWER 11 OF 30 CA COPYRIGHT 2001 ACS
AN 124:223242 CA
TI Effects of various post-treatment by phenylmethylsulfonyl fluoride on delayed neurotoxicity induced by leptophos
AU Piao, Feng Yuan; Kitabatake, Masayoshi; Xie, Xiu Kui; Yamauchi, Toru
CS School Medicine, Mie University, Edobashi, 514, Japan
SO J. Toxicol. Sci. (1995), 20(5), 609-17
CODEN: JTSCDR; ISSN: 0388-1350
DT Journal
LA English

L35 ANSWER 12 OF 30 CA COPYRIGHT 2001 ACS
AN 124:2746 CA
TI Triphenylphosphite **neuropathy** in hens
AU Fioroni, F.; Moretto, A.; Lotti, M.
CS Ist. Med. Lavoro, Univ. Studi Padova, Padua, I-35127, Italy
SO Arch. Toxicol. (1995), 69(10), 705-11
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English

L35 ANSWER 13 OF 30 CA COPYRIGHT 2001 ACS
AN 123:332411 CA
TI Selective promotion by phenylmethanesulfonyl fluoride of peripheral and spinal cord neuropathies initiated by diisopropyl phosphorofluoridate in the hen
AU Peraica, Maja; Moretto, Angelo; Lotti, Marcello
CS Universita degli Studi di Padova, Istituto di Medicina del Lavoro, Via Facciolati 71, Padua, 35127, Italy
SO Toxicol. Lett. (1995), 80(1-3), 115-21
CODEN: TOLED5; ISSN: 0378-4274
DT Journal
LA English

L35 ANSWER 14 OF 30 CA COPYRIGHT 2001 ACS
AN 123:104746 CA
TI Effect of organophosphorus compounds on **neuropathy** target esterase in hens
AU Sadek, Omayma M.; Abdelhamid, Essam E.; El-Sayed, Mohamed M.; Abdel-Moneam, Nehad M.; Mansour, Nabil A.
CS Faculty of Science, Alexandria University, Egypt
SO Egypt. J. Biochem. (1995), 13(1), 143-52
CODEN: EGJBE4; ISSN: 1012-554X
DT Journal
LA English

=> d l35 25 23 16 all

L35 ANSWER 25 OF 30 CA COPYRIGHT 2001 ACS
AN 104:16305 CA
TI Phenylmethylsulfonyl fluoride protects rats from mipafox-induced delayed **neuropathy**
AU Veronesi, Bellina; Padilla, Stephanie
CS Health Effects Res. Lab., U. S. Environ. Prot. Agency, Research Triangle Park, NC, 27711, USA
SO Toxicol. Appl. Pharmacol. (1985), 81(2), 258-64
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English
CC 4-4 (Toxicology)
AB Prior exposure to a nonaging **neuropathy** target enzyme (NTE) inhibitor, phenylmethylsulfonyl fluoride (PMSF) [**329-98-6**], protectes rats from neurol. damage after subsequent exposure to mipafox [371-86-8]. Adult, male rats were exposed to either PMSF (250 mg/kg, s.c.) or to mipafox (15 mg/kg, i.p.) and a time course of brain NTE inhibition and recovery was defined. A sep. group of PMSF-treated rats was exposed to mipafox when brain NTE inhibition was 87.7%. Conversely, another group of rats, pretreated with mipafox, was dosed with PMSF when NTE inhibition was 90.2%. A 3rd group of animals, treated with PMSF, was exposed to mipafox 14 days later, when NTE activity had recovered to within 10% of control amts. Histopathol. survey (14-21 days postexposure) indicated severed cervical cord damage (damage score .gtoreq.3) in the following frequencies: PMSF, 0%; mipafox, 85%; PMSF-4 h-mipafox, 0%; mipafox-4 h-PMSF, 100%; PMSF-14 days-mipafox, 75%; controls, 0%. These data indicate that PMSF pretreatment protectes rats against mipafox-induced neurol. damage and that the timing of administration and order of presentation are crit. to this protection. Apparently, the initiation of organophosphorus-induced delayed **neuropathy** is a multistage event involving inhibition and aging, and these stages are exptl. separable.
ST mipafox neurotoxicity phenylmethylsulfonyl fluoride
IT Brain, composition
(**neuropathy** target enzyme of, mipafox effect on, phenylmethylsulfonyl fluoride in relation to)
IT Spinal cord
(cervical, mipafox toxicity to, phenylmethylsulfonyl fluoride protection against)
IT **329-98-6**
RL: BIOL (Biological study)
(mipafox neurotoxicity protection by)
IT 9013-79-0
RL: BIOL (Biological study)
(neurotoxic, of brain, mipafox effect on, phenylmethylsulfonyl fluoride

in relation to)
IT 371-86-8
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(neurotoxicity of, phenylmethylsulfonyl fluoride protection against)

L35 ANSWER 23 OF 30 CA COPYRIGHT 2001 ACS
AN 110:149296 CA
TI Triphenyl phosphite neurotoxicity in the hen: inhibition of neurotoxic esterase and of prophylaxis by phenylmethylsulfonyl fluoride
AU Carrington, Clark D.; Abou-Donia, Mohamed B.
CS Med. Cent., Duke Univ., Durham, NC, 27710, USA
SO Arch. Toxicol. (1988), 62(5), 375-80
CODEN: ARTODN; ISSN: 0340-5761
DT Journal
LA English
CC 4-3 (Toxicology)
AB The neuropathic syndrome resulting in the cat and the rat from single or multiple doses of the phosphorous acid ester tri-Ph phosphite (TPP) has been reported to differ from the syndrome caused by numerous phosphoric acid esters, which is known as organophosphorous compd.-induced delayed neurotoxicity (OPIDN). Since the hen is used to test compds. for OPIDN, the neurotoxicity of single s.c. doses of TPP was studied using this animal model. TPP (1000 mg/kg) produced progressive ataxia and paralysis which began to develop 5-10 days after dosing. Similar signs were obsd. when s.c. doses of the OPIDN-causing agents tri-o-cresyl phosphate (TOCP) or diisopropyl phosphorofluoridate (DFP) were administered. The min. neurotoxic dose of TPP was 500 mg/kg. Prior administration of phenylmethylsulfonyl fluoride (PMSF) prevented the development of a **neuropathy** induced by DFP, but did not fully protect the hens from TPP or TOCP. PMSF slowed, but did not prevent, the **neuropathy** caused by TOCP. PMSF reduced the neurotoxicity of 500 mg/kg TPP, but increased the neurotoxicity of 1000 mg/kg TPP. TPP was a very potent inhibitor of neurotoxic esterase (NTE), the putative target site for OPIDN, in vitro, with a ki of .apprx.2.1 .times. 105 M-1 min-1. Equimolar doses of either TPP (1000 mg/kg) and TOCP (1187 mg/kg) caused over 80% inhibition of neurotoxic esterase (NTE) in brain and sciatic nerve. This high level of NTE inhibition persisted for several weeks. This prolonged inhibition probably accounts for the inability of PMSF to block the neurotoxicity of TOCP. The dose-response curve for NTE inhibition 48 h after dosing indicated that a level of 70% inhibition correlated with the neurotoxicity of TPP. Subneurotoxic doses of TPP and DFP had an additive effect which could be blocked by PMSF. These results indicate that TPP can cause OPIDN in the hen. The synergism between PMSF and the higher dose of TPP suggests the presence of a 2nd neurotoxic effect as well.
ST triphenyl phosphite neurotoxicity chicken phenylmethylsulfonyl fluoride; neurotoxic esterase triphenyl phosphite chicken
IT Paralysis
(from tri-Ph phosphite, in hen, phenylmethylsulfonyl fluoride effect on)
IT Brain, composition
(neurotoxic esterase of, of hen, tri-Ph phosphite effect on)
IT Chicken
(tri-Ph phosphite neurotoxicity in, phenylmethylsulfonyl fluoride effect on)
IT Nervous system
(disease, ataxia, from tri-Ph phosphite, in hen, phenylmethylsulfonyl fluoride effect on)
IT Nerve, toxic chemical and physical damage
(**neuropathy**, from tri-Ph phosphite, in hen, phenylmethylsulfonyl fluoride effect on)
IT Organic compounds, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(phosphorus-contg., neurotoxicity of, in hen, phenylmethylsulfonyl fluoride effect on)
IT Nerve, composition
(sciatic, neurotoxic esterase of, of hen, tri-Ph phosphite effect on)
IT 9013-79-0, Esterase
RL: BIOL (Biological study)
(neurotoxic, of brain and sciatic nerve of hen, tri-Ph phosphite effect on)
IT 101-02-0, Triphenyl phosphite
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(neurotoxicity of, in hen, phenylmethylsulfonyl fluoride effect on)
IT 55-91-4, DFP 78-30-8, TOCP
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(neurotoxicity of, in hen, phenylmethylsulfonyl fluoride effect on, tri-Ph phosphite in relation to)
IT **329-98-6**, Phenylmethylsulfonyl fluoride
RL: BIOL (Biological study)
(triphenylphosphite neurotoxicity response to, in hen)

L35 ANSWER 16 OF 30 CA COPYRIGHT 2001 ACS
AN 119:153659 CA
TI Prophylaxis against and promotion of organophosphate-induced delayed **neuropathy** by phenyl di-n-pentylphosphinate
AU Johnson, M. K.; Read, D. J.
CS MRC Toxicol. Unit, Univ. Leicester, Leicester, LE1 9HN, UK
SO Chem.-Biol. Interact. (1993), 87(1-3), 449-55
CODEN: CBINA8; ISSN: 0009-2797
DT Journal
LA English
CC 4-3 (Toxicology)
AB Ph di-n-pentylphosphinate (PPP) is a potent inhibitor of **neuropathy** target esterase (NTE) with a negligible effect on acetylcholinesterase; I50s at 37.degree.C for 20 min and pH 8, resp. are 0.2 .mu.M and >2mM. PPP is not neuropathic. This is compatible with the fact that inhibited NTE in autopsy material from hens dosed with PPP can always be reactivated in vitro, presumably because no 'aging' reaction has occurred. PPP (10 mg/kg s.c.) given to hens up to 4 days before severely neuropathic doses (1.7 mg/kg) of diisopropylphosphorofluoridate (DFP) prevented neuropathic but not cholinergic effects of DFP. Hens given PPP 3 days after a sub-neuropathic dose of DFP (0.4 mg/kg) developed severe clin. **neuropathy** (clin. scores of 7 and 5 compared with DFP-plus-solvent scores 0, 1, 3). These prophylactic and promoting effects are similar to those exerted by phenylmethanesulfonyl fluoride (PMSF) at doses which inhibit NTE. In 3 out of 4 birds, a pre-dose with PMSF (15 mg/kg) prevented the promoting effect of 120 mg/kg PMSF given after DFP.
ST phenyl dipentylphosphinate **neuropathy**
IT Nerve, disease
(**neuropathy**, from Ph dipentylphosphinate, prophylaxis against)
IT 55-91-4, Diisopropylphosphorofluoridate **329-98-6**, Phenylmethanesulfonyl fluoride
RL: BIOL (Biological study)
(**neuropathy** by Ph dipentylphosphonate prevention by)
IT 14656-17-8
RL: BIOL (Biological study)
(**neuropathy** from, prophylaxis against)

=> s l29 and l10

L36 0 L29 AND L10

=> s l21 and l22

L37 350 L21 AND L22

=> s l21 or l22

L38 36331 L21 OR L22

=> s l38 and l10

L39 4 L38 AND L10

=> d l39 1-4

L39 ANSWER 1 OF 4 CA COPYRIGHT 2001 ACS
AN 133:248681 CA
TI Human brain-associated inhibitor of tissue-type plasminogen activator (BAIT) and cDNA and their use for treatment of **stroke**
IN Lawrence, Daniel A.; Yepes, Manuel; Sandkvist, Maria; Coleman, Timothy A.;
Wong, Michael K. K.
PA Human Genome Sciences, Inc., USA; American Red Cross
SO PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000053793	A1	20000914	WO 2000-US5956	20000308

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-123704 19990310
RE.CNT 1
RE
(1) Hastings; US 6008020 1999 CA

L39 ANSWER 2 OF 4 CA COPYRIGHT 2001 ACS
AN 133:232282 CA
TI Serine protease inhibitors: novel therapeutic targets for **stroke**?
AU Vivien, Denis; Buisson, Alain
CS Universite de Caen, Caen, 14074, Fr.
SO J. Cereb. Blood Flow Metab. (2000), 20(5), 755-764
CODEN: JCBMDN; ISSN: 0271-678X
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 69
RE
(2) Baranes, D; Neuron 1998, V21, P813 CA
(3) Berger, P; Gene 1998, V214, P25 CA
(4) Buisson, A; FASEB J 1998, V12, P1683 CA

(6) Carmeliet, P; Nature 1994, V368, P419 CA
(7) Chen, Z; Cell 1997, V91, P917 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 3 OF 4 CA COPYRIGHT 2001 ACS
AN 133:187780 CA
TI Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis
AU Yepes, Manuel; Sandkvist, Maria; Wong, Mike K. K.; Coleman, Timothy A.; Smith, Elizabeth; Cohan, Stanley L.; Lawrence, Daniel A.
CS Department of Biochemistry, American Red Cross Holland Laboratory, Rockville, MD, 20855, USA
SO Blood (2000), 96(2), 569-576
CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology
DT Journal
LA English
RE.CNT 70
RE
(1) Ahn, M; Brain Res 1999, V837, P169 CA
(3) Benveniste, H; J Neurochem 1984, V43, P1369 CA
(5) Calof, A; Neuron 1994, V13, P117 CA
(7) Carroll, P; Development 1994, V120, P3173 CA
(8) Chen, Z; Cell 1997, V91, P917 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
AN 131:139510 CA
TI Neuroserpin applications as a pharmaceutical or diagnostic agent
IN Sonderegger, Peter; Schrimpf, Sabine Petra; Kruger, Stefan Robert; Osterwalder, Thomas; Stockli, Esther Trudi
PA Switz.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9941381	A1	19990819	WO 1999-IB248	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9921807	A1	19990830	AU 1999-21807	19990212
PRAI	US 1998-23129		19980213		
	WO 1999-IB248		19990212		

RE.CNT 6
RE
(1) Coleman, T; WO 9816643 A 1998 CA
(2) Hastings, G; THE JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(52), P33062 CA
(3) Incyte Pharma Inc; WO 9640922 A 1996 CA
(4) Krueger, S; THE JOURNAL OF NEUROSCIENCE 1997, V17(23), P8984 CA
(6) Schrimpf; GENOMICS 1997, V40(1), P55 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 139 4 all

L39 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
AN 131:139510 CA
TI Neuroserpin applications as a pharmaceutical or diagnostic agent
IN Sonderegger, Peter; Schrimpf, Sabine Petra; Kruger, Stefan Robert; Osterwalder, Thomas; Stockli, Esther Trudi
PA Switz.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-15
ICS C07K014-81; A61K038-17; A61K048-00; A01K067-027
CC 1-11 (Pharmacology)
Section cross-reference(s): 3, 7
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9941381	A1	19990819	WO 1999-IB248	19990212

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9921807	A1	19990830	AU 1999-21807	19990212

PRAI US 1998-23129 19980213
WO 1999-IB248 19990212

AB Pharmaceutical and diagnostic applications of neuroserpins, in particular human neuroserpin, are provided. Neuroserpin expression is enhanced in neurons of the ipsilateral hemisphere after focal ischemia **stroke**. In the adult brain, neuroserpin and tissue-type plasminogen activator (tPA) for complexes. Overexpression of neuroserpin in central nervous system neurons using transgenic mice technol. results in reduced tPA activity in the brain and an attenuated microglial activation in the reactive zone of a focal ischemic **stroke**. Thus, neuroserpins are valuable agents in the treatment of disorders of the nervous system, in particular the central nervous system. They are very useful in the treatment of **stroke** and for the development of drugs.

ST neuroserpin pharmacol diagnosis nervous system; sequence neuroserpin cDNA human mouse; drug screening neuroserpin nervous system; **stroke** treatment neuroserpin

IT Diagnosis
(agents; neuroserpin applications as a pharmaceutical or diagnostic agent)

IT Antitumor agents
(brain; neuroserpin applications as a pharmaceutical or diagnostic agent)

IT Nervous system
(central, disease, treatment of; neuroserpin applications as a pharmaceutical or diagnostic agent)

IT Neuron
(death, prevention of; neuroserpin applications as a pharmaceutical or diagnostic agent)

IT Nervous system
(disease, treatment of; neuroserpin applications as a pharmaceutical or diagnostic agent)

IT cDNA sequences

(for neuroserpin from human and mouse)
IT Brain, neoplasm
(inhibitors; neuroserpin applications as a pharmaceutical or diagnostic
agent)
IT Blood vessel, neoplasm
(metastasis inhibitors; neuroserpin applications as a pharmaceutical or
diagnostic agent)
IT Antitumor agents
Drug screening
Drugs
Molecular cloning
Mouse
(neuroserpin applications as a pharmaceutical or diagnostic agent)
IT Protein sequences
(of neuroserpin from human and mouse)
IT Antibodies
Antigens
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(prodn. of; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT Escherichia coli
Eukaryote (Eukaryotae)
(recombinant expression host; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT Brain, disease
(**stroke**, treatment or prevention of tissue destruction in; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT Animal
(transgenic; neuroserpin applications as a pharmaceutical or diagnostic
agent)
IT Angiogenesis
Brain, disease
(treatment of; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT **188310-87-4**, Neuroserpin (human gene PI12 precursor)
188364-82-1, Neuroserpin **200890-63-7**, Neuroserpin (mouse strain BALB/c brain)
RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT 9001-12-1, Collagenase 9001-90-5, Plasmin 9004-06-2, Elastase 9025-26-7, Cathepsin D 9032-92-2, Glycosidase 9039-53-6, Urokinase 9040-48-6, Gelatinase 9047-22-7, Cathepsin B 37353-41-6, Cysteine proteinase 56645-49-9, Cathepsin G 79955-99-0, Stromelysin 139639-23-9, Tissue-type plasminogen activator 139639-24-0, Urokinase-type plasminogen activator 141256-52-2, Matrilysin 141907-41-7, Matrix metalloproteinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(nervous system disorders requiring inhibition of; neuroserpin applications as a pharmaceutical or diagnostic agent)
IT **185376-12-9**, GenBank Z81326 **197679-81-5**, GenBank AJ001700
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; neuroserpin applications as a pharmaceutical or diagnostic agent)
RE.CNT 6

RE
(1) Coleman, T; WO 9816643 A 1998 CA
(2) Hastings, G; THE JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(52), P33062 CA
(3) Incyte Pharma Inc; WO 9640922 A 1996 CA
(4) Krueger, S; THE JOURNAL OF NEUROSCIENCE 1997, V17(23), P8984 CA
(5) Marra, M; EMBL DATABASE ENTRY
(6) Schrimpf; GENOMICS 1997, V40(1), P55 CA

=> s l38 and l11

L40 2 L38 AND L11

=> d l40 1-2

L40 ANSWER 1 OF 2 CA COPYRIGHT 2001 ACS
AN 120:49588 CA
TI Method for processing and preserving collagen-based tissues for transplantation
IN Livesey, Stephen A.; Del Campo, Anthony A.; Nag, Abhijit; Nichols, Ken B.; Griffey, Edward S.; Coleman, Christopher
PA Lifecell Corp., USA
SO Can. Pat. Appl., 63 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2089336	AA	19930813	CA 1993-2089336	19930211
	CA 2051092	AA	19920313	CA 1991-2051092	19910910
	AU 9183797	A1	19920319	AU 1991-83797	19910910
	AU 650045	B2	19940609		
	EP 475409	A2	19920318	EP 1991-115480	19910912
	EP 475409	A3	19930901		
	EP 475409	B1	19980415		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 164981	E	19980515	AT 1991-115480	19910912
	ES 2114868	T3	19980616	ES 1991-115480	19910912
	US 5336616	A	19940809	US 1993-4752	19930202
	AU 9332934	A1	19930819	AU 1993-32934	19930210
	AU 668703	B2	19960516		
	EP 564786	A2	19931013	EP 1993-102264	19930212
	EP 564786	A3	19940706		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06261933	A2	19940920	JP 1993-47373	19930212
	US 5364756	A	19941115	US 1993-18357	19930216
	AU 9467405	A1	19940922	AU 1994-67405	19940713
	AU 677845	B2	19970508		
	US 5780295	A	19980714	US 1996-752740	19961114
	US 6194136	B1	20010227	US 1998-114433	19980713
PRAI	US 1992-835138	19920212			
	US 1993-4752	19930202			
	US 1990-581584	19900912			
	US 1991-709504	19910603			
	US 1993-18357	19930216			
	US 1994-291340	19940817			
	US 1996-18357	19960216			
	US 1996-752740	19961114			

L40 ANSWER 2 OF 2 CA COPYRIGHT 2001 ACS
AN 117:103472 CA
TI A novel cytotoxicity screening assay using a multiwell fluorescence scanner
AU Nieminen, Anna Liisa; Gores, Gregory J.; Bond, John M.; Imberti, Roberto; Herman, Brian; Lemasters, John J.
CS Sch. Med., Univ. North Carolina, Chapel Hill, NC, 27599-7090, USA
SO Toxicol. Appl. Pharmacol. (1992), 115(2), 147-55
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

=> s l38 and l12

L41 0 L38 AND L12

=> s l38 and l13

L42 1 L38 AND L13

=> d 142

L42 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS
AN 117:103472 CA
TI A novel cytotoxicity screening assay using a multiwell fluorescence scanner
AU Nieminen, Anna Liisa; Gores, Gregory J.; Bond, John M.; Imberti, Roberto; Herman, Brian; Lemasters, John J.
CS Sch. Med., Univ. North Carolina, Chapel Hill, NC, 27599-7090, USA
SO Toxicol. Appl. Pharmacol. (1992), 115(2), 147-55
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

=> d 142 1 all

L42 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS
AN 117:103472 CA
TI A novel cytotoxicity screening assay using a multiwell fluorescence scanner
AU Nieminen, Anna Liisa; Gores, Gregory J.; Bond, John M.; Imberti, Roberto; Herman, Brian; Lemasters, John J.
CS Sch. Med., Univ. North Carolina, Chapel Hill, NC, 27599-7090, USA
SO Toxicol. Appl. Pharmacol. (1992), 115(2), 147-55
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English
CC 1-1 (Pharmacology)
AB A new assay using a multiwell fluorescence scanner was developed for screening cytotoxicity to cells cultured in 96-well microtiter plates. The assay is based on binding of propidium iodide to nuclei of cells whose plasma membranes have become permeable due to cell death. Fluorescence of propidium iodide measured with a multiwell fluorescence scanner increased in proportion to the no. of permeabilized cells. After ATP depletion of hepatocytes and neonatal cardiac myocytes with metabolic inhibitors ("chem. **hypoxia**"), and exposure of Madine Darby canine kidney cells to the toxic chem., HgCl2, propidium iodide fluorescence

progressively increased. Increases of fluorescence were linearly proportional with release of lactate dehydrogenase into the culture medium. Employing this cytotoxicity screening assay, protection by various agents against lethal injury was evaluated in cultured hepatocytes during chem. **hypoxia**. Inhibitors of cysteine proteases (i.e., antipain, leupeptin, E-64), serine proteases (i.e., PMSF), and aspartic acid proteases (i.e., pepstatin A) did not protect against chem. **hypoxia**. In contrast, 1,10-phenanthroline, an inhibitor of metalloprotease, markedly protected against the onset of cell death during chem. **hypoxia**. Half-maximal protection after 60 min occurred at 0.5 .mu.M. Phospholipase inhibitors, chlorpromazine (50 .mu.M) and mepacrine (50 .mu.M), also substantially retarded cell killing. U74006F, an inhibitor of lipid peroxidn., slowed cell killing to a lesser extent during chem. **hypoxia** and after oxidative stress with tert-Bu hydroperoxide. Calciphor, a dimer of prostaglandin B1, did not protect against cell killing during chem. **hypoxia** or tert-Bu hydroperoxide toxicity. In conclusion, this high capacity cytotoxicity assay for cells cultured in 96-well microtiter plates is suitable for rapid screening of potential cytoprotective agents in a variety of cell types.

ST cytotoxicity screening assay cytoprotectant hepatocyte cardiomyocyte

IT Bioassay
(cytoprotectants screening by fluorescence, in hepatocyte and cardiomyocyte monolayers)

IT Heart
(cytoprotectants screening in monolayer culture of, using multiwell fluorescence scanner)

IT Leupeptins
RL: PRP (Properties)
(cytoprotective effect of, in cytotoxicity screening assay using multiwell fluorescence scanner)

IT Fluorescence
(cytotoxicity screening assay based on, hepatocyte and cardiomyocyte monolayers in)

IT Cytoprotective agents
(screening of, in cytotoxicity assay using multiwell fluorescence scanner)

IT Toxicity
(cytotoxicity, screening assay using multiwell fluorescence scanner, in hepatocyte and cardiomyocyte monolayers)

IT Liver
(hepatocyte, cytoprotectants screening in monolayer culture of, using multiwell fluorescence scanner)

IT 50-53-3, Chlorpromazine, biological studies 66-71-7, 1,10-Phenanthroline
83-89-6, Mepacrine 329-98-6, PMSF 26305-03-3, Pepstatin A
37691-11-5, Antipain 66701-25-5, E-64 110101-67-2
135608-06-9
RL: PRP (Properties)
(cytoprotective effect of, in cytotoxicity screening assay using multiwell fluorescence scanner)

=> d 138 and 13

'AND' IS NOT A VALID FORMAT FOR FILE 'CA'

The following are valid formats:

ABS --------- GI and AB

ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):bib

L38 ANSWER 13 OF 36331 CA COPYRIGHT 2001 ACS
AN 134:220902 CA
TI Activated coagulation/fibrinolysis system and platelet function in acute thrombotic **stroke** patients with increased C-reactive protein levels
AU Tohgi, H.; Konno, S.; Takahashi, S.; Koizumi, D.; Kondo, R.; Takahashi, H.
CS Department of Neurology, Iwate Medical University, Morioka, Iwate,

027-8505, Japan
SO Thromb. Res. (2000), 100(5), 373-379
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 32
RE
(1) Berk, B; Am J Cardiol 1990, V65, P168 MEDLINE
(2) Booth, N; Br J Haematol 1988, V70, P327 MEDLINE
(3) Bova, I; Stroke 1996, V27, P2204 MEDLINE
(22) Ridker, P; Circulation 1998, V98, P731 CA
(23) Ridker, P; N Engl J Med 1997, V336, P973 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1 11 S NEUROSERPIN
L2 1 S PMSF
L3 1 S APMSF
L4 1 S L3
L5 5 S ANTIPAIN
L6 170 S ANTITHROMBIN
L7 11 S LEUPEPTIN
L8 9 S DICHLOROCOUMARIN
L9 2 S TLCK

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10 17 S L1
E NEUROSERPIN
L11 728 S L2
L12 24 S L3
L13 343 S L5
L14 4326 S L6
L15 171 S L7
L16 16 S L8
L17 372 S L9
E NEUROPATHY
L18 5490 S E3
E EPILEPSY
L19 10805 S E3-E12
E SEIZURE
L20 14562 S E3-E6
E HYPOXIA
L21 24801 S E3
E STROKE
L22 11880 S E3
L23 0 S L17 AND L18
L24 0 S L17 AND L19
L25 0 S L17 AND L20
L26 0 S L17 AND L21
L27 0 S L17 AND L22
L28 0 S L16 AND L18
L29 25960 S L18 OR L19 OR L20
L30 0 S L29 AND L16
L31 0 S L29 AND L15

```
L32           4 S L29 AND L14
L33           0 S L29 AND L13
L34           0 S L29 AND L12
L35          30 S L29 AND L11
L36           0 S L29 AND L10
L37         350 S L21 AND L22
L38       36331 S L21 OR L22
L39           4 S L38 AND L10
L40           2 S L38 AND L11
L41           0 S L38 AND L12
L42           1 S L38 AND L13

=> d 142 1


L42  ANSWER 1 OF 1  CA  COPYRIGHT 2001 ACS
AN   117:103472  CA
TI   A novel cytotoxicity screening assay using a multiwell fluorescence
     scanner
AU   Nieminen, Anna Liisa; Gores, Gregory J.; Bond, John M.; Imberti, Roberto;
     Herman, Brian; Lemasters, John J.
CS   Sch. Med., Univ. North Carolina, Chapel Hill, NC, 27599-7090, USA
SO   Toxicol. Appl. Pharmacol. (1992), 115(2), 147-55
     CODEN: TXAPA9; ISSN: 0041-008X
DT   Journal
LA   English


=> s l38 and l14

L43         46 L38 AND L14

=> d l43 20-46


L43  ANSWER 20 OF 46  CA  COPYRIGHT 2001 ACS
AN   130:276486  CA
TI   Antithrombin-III activity and the efficacy of heparin in progressing
     ischemic stroke
AU   Roden-Jullig, Asa; Britton, Mona; Svensson, Jan
CS   Division of Internal Medicine, Karolinska Institutet Danderyd Hospital,
     Danderyd, S-182 88, Swed.
SO   Clin. Appl. Thromb./Hemostasis (1998), 4(2), 129-132
     CODEN: CATHF9; ISSN: 1076-0296
PB   Lippincott-Raven Publishers
DT   Journal
LA   English
RE.CNT  24
RE
(1) Altes, A; Acta Haematol 1995, V94, P10 MEDLINE
(3) Britton, M; Stroke 1985, V16, P629 MEDLINE
(5) Davalos, A; Neurol 1990, V40, P1865 MEDLINE
(20) Takano, K; Thromb Res 1990, V58, P481 CA
(23) van Wersch, J; Eur J Clin Chem Clin Biochem 1993, V31, P575 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43  ANSWER 21 OF 46  CA  COPYRIGHT 2001 ACS
AN   130:47481  CA
TI   Preparation of modified, low-molecular-weight heparin that inhibits
     clot-associated coagulation factors
IN   Weitz, Jeffrey; Hirsh, Jack
PA   Hamilton Civic Hospitals Research Development, Inc., Can.
SO   PCT Int. Appl., 51 pp.
```

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9855515	A1	19981210	WO 1998-CA548	19980605
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877538	A1	19981221	AU 1998-77538	19980605
EP 986581	A1	20000322	EP 1998-925356	19980605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-72098 19970606
WO 1998-CA548 19980605
RE.CNT 6
RE
(1) Bioiberica SA; EP 0337327 A 1989 CA
(2) Hamilton Civic Hospitals Research Development Inc; EP 0735050 A 1996 CA
(3) Novo Industri A/S; EP 0244235 A 1987 CA
(4) Rhone-Poulenc Rorer SA; EP 0511075 A 1992 CA
(5) Rhone-Poulenc Rorer SA; WO 9316112 A 1993 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 22 OF 46 CA COPYRIGHT 2001 ACS
AN 129:329217 CA
TI Relative influence of age and thrombotic history on hemostatic parameters
AU Javorschi, S.; Richard-Harston, S.; Labrouche, S.; Manciet, G.; Freyburger, G.
CS Laboratoire d'Hematologie, Hopital Pellegrin, Bordeaux, 33076, Fr.
SO Thromb. Res. (1998), 91(5), 241-248
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English

L43 ANSWER 23 OF 46 CA COPYRIGHT 2001 ACS
AN 129:58856 CA
TI Compositions and methods for inhibiting thrombogenesis
IN Weitz, Jeffrey I.; Hirsh, Jack; Young, Edward
PA Hamilton Civic Hospitals Research Development Inc., Can.
SO U.S., 65 pp. Cont.-in-part of U. S. 5,744,457.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5763427	A	19980609	US 1996-624327	19960329
US 5744457	A	19980428	US 1995-540324	19951006
AU 9651400	A1	19961016	AU 1996-51400	19960329
JP 11506420	T2	19990608	JP 1996-528734	19960329
US 6001820	A	19991214	US 1997-870528	19970606
NO 9704500	A	19971128	NO 1997-4500	19970929

PRAI US 1995-412332 19950331
US 1995-540324 19951006
US 1996-624327 19960329

WO 1996-CA190 19960329
OS MARPAT 129:58856

L43 ANSWER 24 OF 46 CA COPYRIGHT 2001 ACS
AN 129:26531 CA
TI Analysis of lipoprotein(a) and coagulation-fibrinolysis system in the **stroke** types or recurrences of the cerebral thrombosis
AU Kashiwaya, Mitsuru; Konno, Shu; Takahashi, Hiroaki
CS Sch. Med., Iwate Med. Univ., Morioka, 020-8505, Japan
SO Iwate Igaku Zasshi (1998), 50(1), 65-71
CODEN: IIZAAX; ISSN: 0021-3284
PB Iwate Igakkai
DT Journal
LA Japanese

L43 ANSWER 25 OF 46 CA COPYRIGHT 2001 ACS
AN 129:3340 CA
TI Pathophysiology and clinical management of fetus with intrauterine growth retardation
AU Takeda, Yoshihiko
CS Dep. Gynecol., Tokyo Women's Med. Coll., Tokyo, 162-8666, Japan
SO Tokyo Joshi Ika Daigaku Zasshi (1998), 68(4), 161-170
CODEN: TJIZAF; ISSN: 0040-9022
PB Tokyo Joshi Ika Daigaku Gakkai
DT Journal; General Review
LA Japanese

L43 ANSWER 26 OF 46 CA COPYRIGHT 2001 ACS
AN 128:312895 CA
TI Compositions and methods for inhibiting thrombogenesis
IN Weitz, Jeffrey I.; Hirsh, Jack; Young, Edward
PA Hamilton Civic Hospitals Research Development Inc., Can.
SO U.S., 67 pp. Cont.-in-part of U.S. Ser. No. 412,332, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5744457	A	19980428	US 1995-540324	19951006
	WO 9629973	A2	19961003	WO 1996-CA190	19960329
	WO 9629973	A3	19961219		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	CA 2217054	AA	19961003	CA 1996-2217054	19960329
	AU 9651400	A1	19961016	AU 1996-51400	19960329
	US 5763427	A	19980609	US 1996-624327	19960329
	CN 1186502	A	19980701	CN 1996-194354	19960329
	JP 11506420	T2	19990608	JP 1996-528734	19960329
	EP 735050	A2	19961002	EP 1996-302311	19960401
	EP 735050	A3	19970122		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	GB 2299998	A1	19961023	GB 1996-6881	19960401
	GB 2299998	B2	19970326		
	US 6001820	A	19991214	US 1997-870528	19970606
	NO 9704500	A	19971128	NO 1997-4500	19970929
PRAI	US 1995-412332	19950331			
	US 1995-485872	19950607			

US 1995-540324 19951006
US 1996-624327 19960329
WO 1996-CA190 19960329
OS MARPAT 128:312895

L43 ANSWER 27 OF 46 CA COPYRIGHT 2001 ACS
AN 128:305295 CA
TI Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by pH and metals
AU Borza, Dorin-Bogdan; Morgan, William T.
CS Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri, Kansas City, MO, 64110, USA
SO J. Biol. Chem. (1998), 273(10), 5493-5499
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L43 ANSWER 28 OF 46 CA COPYRIGHT 2001 ACS
AN 128:97817 CA
TI Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial
AU Scarabin, Pierre-Yves; Alhenc-Gelas, Martine; Plu-Bureau, Genevieve; Taisne, Pascale; Agher, Rachid; Aiach, Martine
CS INSERM-Cardiovascular Epidemiology Unit U258, Hopital Broussais, Paris, Fr.
SO Arterioscler., Thromb., Vasc. Biol. (1997), 17(11), 3071-3078
CODEN: ATVBFA; ISSN: 1079-5642
PB American Heart Association
DT Journal
LA English

L43 ANSWER 29 OF 46 CA COPYRIGHT 2001 ACS
AN 125:325404 CA
TI Hemostatic studies in carbohydrate-deficient glycoprotein syndrome type I
AU Fiumara, A.; Barone, R.; Buttitta, P.; Musso, R.; Pavone, L.; Nigro, F.; Jaeken, J.
CS Department Pediatrics, University Catania, Catania, Italy
SO Thromb. Haemostasis (1996), 76(4), 502-504
CODEN: THHADQ; ISSN: 0340-6245
DT Journal
LA English

L43 ANSWER 30 OF 46 CA COPYRIGHT 2001 ACS
AN 125:317356 CA
TI Heparin preparations for inhibiting thrombogenesis
IN Weitz, Jeffrey I.; Hirsh, Jack; Young, Edward
PA Hamilton Civic Hospitals Research Development, Inc., Can.
SO Eur. Pat. Appl., 76 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 735050	A2	19961002	EP 1996-302311	19960401
	EP 735050	A3	19970122		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5744457	A	19980428	US 1995-540324	19951006
	AU 9651400	A1	19961016	AU 1996-51400	19960329
	JP 11506420	T2	19990608	JP 1996-528734	19960329

NO 9704500 A 19971128 NO 1997-4500 19970929
PRAI US 1995-412332 19950331
US 1995-485872 19950607
US 1995-540324 19951006
WO 1996-CA190 19960329

L43 ANSWER 31 OF 46 CA COPYRIGHT 2001 ACS
AN 125:104648 CA
TI Antithrombin III prevents blood pressure elevation and proteinuria induced
by high salt intake in pregnant **stroke**-prone spontaneously hypertensive rats
AU Shinyama, Hiroshi; Yamanaga, Katsumi; Akira, Toshiaki; Uchida, Takeshi; Yaguchi, Masafumi; Watanabe, Masahrio; Kagitani, Yoshio
CS Pharmacology Labs., Green Cross Corp., Osaka, 573, Japan
SO Biol. Pharm. Bull. (1996), 19(6), 819-823
CODEN: BPBLEO; ISSN: 0918-6158
DT Journal
LA English

L43 ANSWER 32 OF 46 CA COPYRIGHT 2001 ACS
AN 125:83683 CA
TI Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I
AU Stibler, H.; Holzbach, U.; Tengborn, L.; Kristiansson, B.
CS Department Neurology, Karolinska Hospital, Stockholm, S-171 76, Swed.
SO Blood Coagulation Fibrinolysis (1996), 7(2), 118-126
CODEN: BLFIE7; ISSN: 0957-5235
DT Journal
LA English

L43 ANSWER 33 OF 46 CA COPYRIGHT 2001 ACS
AN 125:80523 CA
TI .alpha.1-antitrypsin variants carrying thrombin-specificity peptides from antithrombin III that are inactive against activated protein C
IN Hopkins, Paul C. R.; Carrell, Robin; Crowther, Damian; Stone, Stuart
PA Ppl Therapeutics (Scotland) Ltd., UK
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9610638	A1	19960411	WO 1995-GB2155	19950912
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9534794	A1	19960426	AU 1995-34794	19950912
ZA 9507852	A	19970318	ZA 1995-7852	19950918

PRAI GB 1994-19804 19940930
GB 1995-2138 19950203
WO 1995-GB2155 19950912

L43 ANSWER 34 OF 46 CA COPYRIGHT 2001 ACS
AN 124:6115 CA
TI Lipoprotein(a) and hemostasis activation markers in angina pectoris
AU Tsakiris, D. A.; Riesen, W. F.; Marbet, G. A.
CS Dep. Zentrallab., Univ. Basel, Basel, CH-4031, Switz.

SO Dtsch. Med. Wochenschr. (1995), 120(33), 1109-13
CODEN: DMWOAX; ISSN: 0012-0472
DT Journal
LA English

L43 ANSWER 35 OF 46 CA COPYRIGHT 2001 ACS
AN 121:149109 CA
TI Treatment of neurodegenerative diseases with thrombin inhibitors
IN Friedrich, Thomas
PA BASF A.-G., Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4303646	A1	19940811	DE 1993-4303646	19930209
	WO 9417821	A1	19940818	WO 1994-EP259	19940129
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2153420	AA	19940818	CA 1994-2153420	19940129
	EP 683674	A1	19951129	EP 1994-906174	19940129
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	JP 08507047	T2	19960730	JP 1994-517604	19940129
PRAI	DE 1993-4303646	19930209			
	WO 1994-EP259	19940129			

L43 ANSWER 36 OF 46 CA COPYRIGHT 2001 ACS
AN 120:51584 CA
TI Changes of von Willebrand factor and antithrombin III levels in acute **stroke**: Difference between thrombotic and hemorrhagic **stroke**
AU Liu, Longbin; Lin, Zhusan; Shen, Zeshuang
CS 2nd Affil. Hosp., Hunan Med. Univ., Peop. Rep. China
SO Thromb. Res. (1993), 72(4), 353-8
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L43 ANSWER 37 OF 46 CA COPYRIGHT 2001 ACS
AN 118:94067 CA
TI Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease
AU Orefice, G.; Troisi, E.; Selvaggio, M.; Vecchione, V.; Rubino, S.; Provitera, V.; Carrieri, P. B.
CS 2nd Med. Sch., Univ. Naples, Naples, Italy
SO Curr. Ther. Res. (1992), 52(5), 666-70
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L43 ANSWER 38 OF 46 CA COPYRIGHT 2001 ACS
AN 118:78363 CA
TI Effects of **hypoxia** on heparan sulfate in bovine aortic and pulmonary artery endothelial cells
AU Karlinsky, Joel B.; Rounds, Sharon; Farber, Harrison W.
CS Sch. Med., Boston Univ., Boston, MA, USA
SO Circ. Res. (1992), 71(4), 782-9
CODEN: CIRUAL; ISSN: 0009-7330
DT Journal
LA English

L43 ANSWER 39 OF 46 CA COPYRIGHT 2001 ACS
AN 118:16315 CA
TI Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
IN Loscalzo, Joseph; Pasche, Boris
PA Brigham and Women's Hospital, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218139	A1	19921029	WO 1992-US3009	19920409
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 9218730	A1	19921117	AU 1992-18730	19920409
PRAI	US 1991-682070		19910409		
	WO 1992-US3009		19920409		

L43 ANSWER 40 OF 46 CA COPYRIGHT 2001 ACS
AN 117:168788 CA
TI Protein S deficiency in middle-aged women with **stroke**
AU Green, David; Otoya, Jorge; Oriba, Howard; Rovner, Richard
CS Med. Sch., Northwestern Univ., Chicago, IL, 60611, USA
SO Neurology (1992), 42(5), 1029-33
CODEN: NEURAI; ISSN: 0028-3878
DT Journal
LA English

L43 ANSWER 41 OF 46 CA COPYRIGHT 2001 ACS
AN 114:226557 CA
TI Circadian variations of platelet aggregability and fibrinolytic activity in healthy subjects
AU Jovicic, A.; Mandic, S.
CS Clin. Neurol., Mil. Med. Acad., Belgrade, Yugoslavia
SO Thromb. Res. (1991), 62(1-2), 65-74
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L43 ANSWER 42 OF 46 CA COPYRIGHT 2001 ACS
AN 113:75820 CA
TI Hypercoagulability in acute ischemic **stroke**: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method
AU Takano, Kentaro; Yamaguchi, Takenori; Okada, Yasushi; Uchida, Kagehiro; Kisiel, Walter; Kato, Hisao
CS Res. Inst., Natl. Cardiovasc. Cent., Osaka, Japan
SO Thromb. Res. (1990), 58(5), 481-91
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L43 ANSWER 43 OF 46 CA COPYRIGHT 2001 ACS
AN 108:34244 CA
TI Heparin cofactor II: a simple assay method and results of its clinical application
AU Vinazzer, H.; Pangraz, U.
CS Blood Coagulation Lab., Linz, Austria
SO Thromb. Res. (1987), 48(2), 153-60
CODEN: THBRAA; ISSN: 0049-3848
DT Journal

LA English

L43 ANSWER 44 OF 46 CA COPYRIGHT 2001 ACS
AN 89:3808 CA
TI Some characteristics of blood coagulation in people under high-altitude conditions determined by the processing of data in a computer
AU Isabaeva, V. A.; Prizhivoit, G. N.; Gurovich, T. Ts.; Prizhivoit, Ya. I.; Shablovskii, V. I.
CS Kirg. Med. Inst., Frunze, USSR
SO Tr. Kirg. Gos. Med. Inst. (1976), 110, 87-94
CODEN: TKRMAS; ISSN: 0371-8778
DT Journal
LA Russian

L43 ANSWER 45 OF 46 CA COPYRIGHT 2001 ACS
AN 89:3807 CA
TI The blood clotting system during high-altitude adaptation and readaptation
AU Isabaeva, V. A.; Ponomareva, T. A.
CS Kirg. Med. Inst., Frunze, USSR
SO Tr. Kirg. Gos. Med. Inst. (1976), 110, 77-87
CODEN: TKRMAS; ISSN: 0371-8778
DT Journal
LA Russian

L43 ANSWER 46 OF 46 CA COPYRIGHT 2001 ACS
AN 85:91728 CA
TI Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in **stroke**
AU Fletcher, Anthony P.; Alkjaersig, Norma; Davies, Andrew; Lewis, Martin; Brooks, John; Hardin, William; Landau, William; Raichle, Marcus E.
CS Sch. Med., Washington Univ., St. Louis, Mo., USA
SO Stroke (1976), 7(4), 337-48
CODEN: SJCCA7
DT Journal
LA English

=> d 143 46 42 36 30 26 24 all

L43 ANSWER 46 OF 46 CA COPYRIGHT 2001 ACS
AN 85:91728 CA
TI Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in **stroke**
AU Fletcher, Anthony P.; Alkjaersig, Norma; Davies, Andrew; Lewis, Martin; Brooks, John; Hardin, William; Landau, William; Raichle, Marcus E.
CS Sch. Med., Washington Univ., St. Louis, Mo., USA
SO Stroke (1976), 7(4), 337-48
CODEN: SJCCA7
DT Journal
LA English
CC 14-7 (Mammalian Pathological Biochemistry)
AB Plasma fibrinogen chromatog. is a method for quantification of high mol. wt. fibrinogen complexes (HMWFC), native fibrinogen and other fibrinogen derivs. in plasma. The method distinguishes between subjects with normal and pathol. rates of fibrin formation. Serial std. blood coagulation assays, including plasma fibrinogen chromatog., and neurol. studies were performed on 220 patients admitted to a **stroke** unit. Findings from patients with cerebral infarction were compared against those of 3 control groups: normals, a **stroke** control group, and a

stroke risk factor group. Plasma HMWFC findings were higher in the **stroke** risk factor group than in the normals. Plasma HMWFC values were higher in the cerebral infarction patients than in any of the control groups, and plasma fibrinogen, plasminogen, .alpha.1-antitrypsin and .alpha.2-macroglobulin also were higher in the patients. The greater the degree of initial neurol. deficit, the greater were plasma HMWFC values, and high HMWFC values were associated with poor clin. outcome. Plasma HMWFC values were higher in patients with intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral embolism. Thus, a high proportion of **stroke** patients have coagulopathy, characterized by pathol. enhancement of fibrin formation.

ST **stroke** plasma fibrinogen chromatog; blood coagulation chromatog **stroke**

IT Macroglobulins
RL: BIOL (Biological study)
(.alpha.2-, in brain circulatory disease)

IT Brain, disease or disorder
(circulatory, blood coagulation and fibrinolysis in)

IT Fibrinolysis
Fibrinogens
RL: BIOL (Biological study)
(in brain circulatory disease)

IT **9000-94-6**
RL: BIOL (Biological study)
(III, in brain circulatory disease)

IT 9001-91-6 9041-92-3
RL: BIOL (Biological study)
(in brain circulatory disease)

L43 ANSWER 42 OF 46 CA COPYRIGHT 2001 ACS

AN 113:75820 CA

TI Hypercoagulability in acute ischemic **stroke**: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method

AU Takano, Kentaro; Yamaguchi, Takenori; Okada, Yasushi; Uchida, Kagehiro; Kisiel, Walter; Kato, Hisao

CS Res. Inst., Natl. Cardiovasc. Cent., Osaka, Japan

SO Thromb. Res. (1990), 58(5), 481-91
CODEN: THBRAA; ISSN: 0049-3848

DT Journal

LA English

CC 14-6 (Mammalian Pathological Biochemistry)

AB The coagulability of plasma from 63 patients with acute ischemic **stroke** (cerebral thrombosis and cerebral embolism) was analyzed by an automated method for prothrombin time using a fluorogenic peptide substrate. The fluorogenic prothrombin time (FPT) of plasma collected within 48 h after onset, as expressed as percent of control plasma, was significantly higher in cerebral thrombosis than in an age-matched control group. The high values of FPT in cerebral thrombosis patients were obsd. until the 30th day after onset. On the other hand, FPT values in cerebral embolism patients were not significantly different than that of the control group. Factor VII activity levels in cerebral thrombosis patients were significantly higher than those of the control group and cerebral embolism patients, while levels of factor X activity were not significantly different among these groups. Although FPT and factor VII activity in these **stroke** patients did not significantly correlate, factor VII activity did correlate well with factor VII antigen. Decreased levels of antithrombin III and elevated levels of FDP and

.alpha.2-antiplasmin-plasmin complexes were obsd. only in cerebral embolism patients. The findings strongly suggest that patients with cerebral thrombosis have been in a hypercoagulable state before the onset of symptoms, which was caused in part by an increase of factor VII activity/antigen, and in part by other unknown mechanisms. In contrast, patients with cerebral embolism were in a low grade consumptive coagulopathy.

ST brain thrombosis blood coagulation factor VII; hypercoagulability **stroke** blood coagulation factor VII

IT Fibrinogen degradation products
RL: BIOL (Biological study)
(in ischemic **stroke** from cerebral embolism, of humans, low grade consumptive coagulopathy in relation to)

IT Embolism
(ischemic **stroke** of brain from, antithrombin III and fibrinogen degrdn. products and .alpha.2-antiplasmin-plasmin complexes of blood plasma and low grade consumptive coagulopathy in relation to, of humans)

IT Thrombosis
(ischemic **stroke** of brain from, blood-coagulation factor VII of blood plasma and hypercoagulability in relation to, of human)

IT Blood coagulation
(disorder, disseminated intravascular, antithrombin III and fibrinogen degrdn. product and .alpha.2-antiplasmin-plasmin complexes of blood plasma in ischemic **stroke** from cerebral embolism of human in relation to)

IT Blood coagulation
(disorder, hypercoagulability, blood-coagulation factor VII of blood plasma in ischemic **stroke** from thrombosis of humans in relation to)

IT Brain, disease or disorder
(embolism, ischemic **stroke** from, antithrombin III and fibrinogen degrdn. products and .alpha.2-antiplasmin-plasmin complexes of blood plasma and low grade consumptive coagulopathy in relation to, of humans)

IT Brain, disease or disorder
(**stroke**, from embolism or thrombosis, extrinsic coagulation factors of blood plasma in, of humans, coagulopathy in relation to)

IT Brain, disease or disorder
(thrombosis, ischemic **stroke** from, blood-coagulation factor VII and hypercoagulability in relation to, of humans)

IT **9000-94-6**, Antithrombin
RL: BIOL (Biological study)
(in ischemic **stroke** from cerebral embolism, of humans, low grade consumptive coagulopathy in relation to)

IT 9001-25-6, Blood-coagulation factor VII
RL: BIOL (Biological study)
(in ischemic **stroke** from cerebral thrombosis, of humans, hypercoagulability in relation to)

IT 9001-90-5, Plasmin
RL: BIOL (Biological study)
(.alpha.2-antiplasmin complexes, in ischemic **stroke** from cerebral embolism, of humans, low grade consumptive coagulopathy in relation to)

L43 ANSWER 36 OF 46 CA COPYRIGHT 2001 ACS
AN 120:51584 CA
TI Changes of von Willebrand factor and antithrombin III levels in acute **stroke**: Difference between thrombotic and hemorrhagic **stroke**
AU Liu, Longbin; Lin, Zhusan; Shen, Zeshuang
CS 2nd Affil. Hosp., Hunan Med. Univ., Peop. Rep. China
SO Thromb. Res. (1993), 72(4), 353-8

CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English
CC 14-6 (Mammalian Pathological Biochemistry)
AB In the present study, the authors measured plasma von Willebrand factor (vWF) levels, concns. and activities. of Antithrombin III (ATIII) in the acute phase of thrombotic and hemorrhagic **stroke** prior to any therapy. The authors' results demonstrate that vWF levels are increased in both thrombotic and hemorrhagic **stroke**, and that vWF and ATIII levels differ between thrombotic and hemorrhagic **stroke** in patients with high incidence of atherosclerosis.
ST von Willebrand antithrombin thrombotic hemorrhagic **stroke**
IT Brain, disease
(hemorrhagic **stroke**, antithrombin III and von Willebrand factor of blood plasma in, in human)
IT Brain, disease
(thrombotic **stroke**, antithrombin III and von Willebrand factor of blood plasma in, in human)
IT 109319-16-6
RL: BIOL (Biological study)
(of blood plasma, in human hemorrhagic and thrombotic **stroke**, antithrombin III in relation to)
IT **9000-94-6**, Antithrombin III
RL: BIOL (Biological study)
(of blood plasma, in human hemorrhagic and thrombotic **stroke**, von Willebrand factor in relation to)

L43 ANSWER 30 OF 46 CA COPYRIGHT 2001 ACS
AN 125:317356 CA
TI Heparin preparations for inhibiting thrombogenesis
IN Weitz, Jeffrey I.; Hirsh, Jack; Young, Edward
PA Hamilton Civic Hospitals Research Development, Inc., Can.
SO Eur. Pat. Appl., 76 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C08B037-10
ICS A61K031-725
CC 1-8 (Pharmacology)
Section cross-reference(s): 33
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 735050	A2	19961002	EP 1996-302311	19960401
	EP 735050	A3	19970122		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5744457	A	19980428	US 1995-540324	19951006
	AU 9651400	A1	19961016	AU 1996-51400	19960329
	JP 11506420	T2	19990608	JP 1996-528734	19960329
	NO 9704500	A	19971128	NO 1997-4500	19970929
PRAI	US 1995-412332	19950331			
	US 1995-485872	19950607			
	US 1995-540324	19951006			
	WO 1996-CA190	19960329			

AB Compns. are provided for inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is a substantially diminished or eliminated. The compns. are particularly useful for preventing thrombosis in the circuit of cardiac bypass app. and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as

unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (**stroke**), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc. The compns. comprise agents which activate heparin cofactor II-mediated inhibition of thrombin and having minimal affinity for antithrombin III. Preferred agents are low mol. wt. heparin prepns. (MW of 3,000-8,000) prepd. by depolymg. heparin using nitrous acid, oxidizing the resultant product with periodate and reducing it with borohydride. The product has its non-sulfated uronic acid residues in open ring form and it substantially free of aldehyde groups.

ST heparin deriv prepn thrombogenesis inhibition

IT Blood platelet
(factor Xa binding to; heparin prepns. for inhibiting thrombogenesis)

IT Anticoagulants and Antithrombotics
Cardiovascular agents
Drug interactions
Oxidizing agents
Pharmaceutical dosage forms
Reducing agents
(heparin prepns. for inhibiting thrombogenesis)

IT Desmins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heparin prepns. for inhibiting thrombogenesis)

IT Depolymerization
(nitrous acid; heparin prepns. for inhibiting thrombogenesis)

IT Anhydrides
RL: RCT (Reactant)
(oxidizing agent; heparin prepns. for inhibiting thrombogenesis)

IT Uronic acids
RL: PRP (Properties)
(polyanionic carbohydrate contg.; heparin prepns. for inhibiting thrombogenesis)

IT Fibrins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(polymn.; heparin prepns. for inhibiting thrombogenesis)

IT Hydrides
RL: RCT (Reactant)
(reducing agent; heparin prepns. for inhibiting thrombogenesis)

IT Thrombus and Blood clot
(thrombin bound to; heparin prepns. for inhibiting thrombogenesis)

IT Carbohydrates and Sugars, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anionic, heparin prepns. for inhibiting thrombogenesis)

IT Circulation
(extracorporeal, cardiopulmonary bypass, heparin prepns. for inhibiting thrombogenesis)

IT 9002-05-5, Blood coagulation factor Xa
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(binding to platelet surface; heparin prepns. for inhibiting thrombogenesis)

IT 9002-04-4, Thrombin
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(clot-bound; heparin prepns. for inhibiting thrombogenesis)

IT 7782-77-6, Nitrous acid
RL: RCT (Reactant)
(depolymn.; heparin prepns. for inhibiting thrombogenesis)

IT 8001-27-2, Hirudin
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)
(heparin prepns. for inhibiting thrombogenesis)
IT 9005-49-6, Heparin, biological studies 9005-49-6D, Heparin, derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heparin prepns. for inhibiting thrombogenesis)
IT **9000-94-6**, Antithrombin III 37203-61-5, Blood coagulation factor XIa 37316-87-3, Blood coagulation factor IXa 81604-65-1, Heparin cofactor II
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(heparin prepns. for inhibiting thrombogenesis)
IT 50-81-7, Ascorbic acid, reactions 67-68-5, Dimethyl sulfoxide, reactions
546-67-8, Lead tetraacetate 7790-28-5, Sodium periodate
RL: RCT (Reactant)
(oxidizing agent; heparin prepns. for inhibiting thrombogenesis)
IT 41107-82-8
RL: PRP (Properties)
(polyanionic carbohydrate contg.; heparin prepns. for inhibiting thrombogenesis)
IT 302-01-2, Hydrazine, reactions 16853-85-3, Lithium aluminum hydride 16940-66-2, Sodium borohydride
RL: RCT (Reactant)
(reducing agent; heparin prepns. for inhibiting thrombogenesis)

L43 ANSWER 26 OF 46 CA COPYRIGHT 2001 ACS
AN 128:312895 CA
TI Compositions and methods for inhibiting thrombogenesis
IN Weitz, Jeffrey I.; Hirsh, Jack; Young, Edward
PA Hamilton Civic Hospitals Research Development Inc., Can.
SO U.S., 67 pp. Cont.-in-part of U.S. Ser. No. 412,332, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-725
ICS C08B037-10
NCL 514056000
CC 63-3 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5744457	A	19980428	US 1995-540324	19951006
	WO 9629973	A2	19961003	WO 1996-CA190	19960329
	WO 9629973	A3	19961219		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	CA 2217054	AA	19961003	CA 1996-2217054	19960329
	AU 9651400	A1	19961016	AU 1996-51400	19960329
	US 5763427	A	19980609	US 1996-624327	19960329
	CN 1186502	A	19980701	CN 1996-194354	19960329
	JP 11506420	T2	19990608	JP 1996-528734	19960329
	EP 735050	A2	19961002	EP 1996-302311	19960401
	EP 735050	A3	19970122		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	GB 2299998	A1	19961023	GB 1996-6881	19960401
	GB 2299998	B2	19970326		
	US 6001820	A	19991214	US 1997-870528	19970606

NO 9704500 A 19971128 NO 1997-4500 19970929
PRAI US 1995-412332 19950331
US 1995-485872 19950607
US 1995-540324 19951006
US 1996-624327 19960329
WO 1996-CA190 19960329
OS MARPAT 128:312895
AB The present invention provides compns. and methods for inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is substantially diminished or eliminated. The compns. contg. heparin cofactor II-specific catalysts are particularly useful for preventing thrombosis in the circuit of cardiac bypass app. and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (**stroke**), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc. The heparin prepns. consist of the lowest 1/3 mol. wt. fraction isolated from unfractionated heparin.
ST antithrombogenic heparin prepn
IT Extracorporeal circulation
(cardiopulmonary bypass; heparin fractions for inhibiting thrombogenesis)
IT Anticoagulants
Dialysis
Oxidizing agents
Reducing agents
Thrombolytics
(heparin fractions for inhibiting thrombogenesis)
IT Anhydrides
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process)
(oxidizing agents; heparin fractions for inhibiting thrombogenesis)
IT Hydrides
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process)
(reducing agents; heparin fractions for inhibiting thrombogenesis)
IT 81604-65-1, Heparin cofactor II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(catalysts for; heparin fractions for inhibiting thrombogenesis)
IT 9005-49-6, Heparin, biological studies
RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(heparin fractions for inhibiting thrombogenesis)
IT **9000-94-6**, Antithrombin III
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heparin fractions for inhibiting thrombogenesis)
IT 50-81-7, Ascorbic acid, reactions 67-68-5, Dmso, reactions 546-67-8, Lead tetraacetate 7790-28-5, Sodium periodate
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process)
(oxidizing agent; heparin fractions for inhibiting thrombogenesis)
IT 302-01-2, Hydrazine, reactions 16853-85-3, Lithium aluminum hydride 16940-66-2, Sodium borohydride
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process)
(reducing agent; heparin fractions for inhibiting thrombogenesis)

L43 ANSWER 24 OF 46 CA COPYRIGHT 2001 ACS

AN 129:26531 CA
TI Analysis of lipoprotein(a) and coagulation-fibrinolysis system in the **stroke** types or recurrences of the cerebral thrombosis
AU Kashiwaya, Mitsuru; Konno, Shu; Takahashi, Hiroaki
CS Sch. Med., Iwate Med. Univ., Morioka, 020-8505, Japan
SO Iwate Igaku Zasshi (1998), 50(1), 65-71
CODEN: IIZAAX; ISSN: 0021-3284
PB Iwate Igakkai
DT Journal
LA Japanese
CC 14-5 (Mammalian Pathological Biochemistry)
AB We studied the serum level of lipoprotein(a) and fibrinolysis system in 235 non-embolic cerebral thrombosis patients diagnosed by CT scans at the initial **stroke**. One hundred and 56 of them were followed up for 3.1 .+-. 2.7 yr, and the rate of symptomatic and asymptomatic reinfarcts was also studied. Sixty out of 235 patients (26%) had the Lp(a) levels .gtoreq.20 mg/dL. There was no significant difference in the location of cerebral infarction between patients with Lp(a) levels <20 mg/dL and those with Lp(a) levels .gtoreq.20 mg/dL. The relative risk of reinfarct in patients with Lp(a) .gtoreq.20 mg/dL compared with those with Lp(a) <20 mg/dL was significantly greater for symptomatic reinfarct ($p < 0.05$), but not for asymptomatic reinfarct. The concn. of fibrinogen and the thrombin-antithrombin complex were higher in patients with Lp(a) .gtoreq.20 mg/dL than those with Lp(a) <20 mg/dL in the acute and chronic phases ($p < 0.05$). The plasmin-.alpha.2 inhibitor complex and D dimer levels were significantly higher in patients with high-Lp(a) levels in chronic phase ($p < 0.05$). These results suggest that elevated Lp(a) levels predisposed symptomatic reinfarct, and were assocd. with a greater activation of the coagulation system in the acute and chronic phases, and of the fibrinolysis system in the chronic phase in cerebral thrombosis.
ST lipoprotein a cerebral thrombosis coagulation fibrinolysis; plasmin alpha2 fibrinogen thrombin antithrombin Lpa
IT High-density lipoproteins
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(cholesterol; serum lipoprotein (a) and coagulation-fibrinolysis system in **stroke** types or recurrences of cerebral thrombosis)
IT Cerebral artery
Fibrinolysis
Stroke
(serum lipoprotein (a) and coagulation-fibrinolysis system in **stroke** types or recurrences of cerebral thrombosis)
IT Blood cholesterol
Blood triglycerides
D-dimer (fibrinogen degradation product)
Fibrinogens
Lipoprotein(a)
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(serum lipoprotein (a) and coagulation-fibrinolysis system in **stroke** types or recurrences of cerebral thrombosis)
IT 57-88-5, Cholesterol, biological studies **9000-94-6D**, Antithrombin III, thrombin complex 9001-90-5D, Plasmin, .alpha.2-plasmin inhibitor complexes 9002-04-4D, Thrombin, antithrombin III complex 138757-15-0D, .alpha.2-Plasmin inhibitor, plasmin complexes
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(serum lipoprotein (a) and coagulation-fibrinolysis system in

stroke types or recurrences of cerebral thrombosis)

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001

```
L1            11 S NEUROSERPIN
L2             1 S PMSF
L3             1 S APMSF
L4             1 S L3
L5             5 S ANTIPAIN
L6           170 S ANTITHROMBIN
L7            11 S LEUPEPTIN
L8             9 S DICHLOROCOUMARIN
L9             2 S TLCK
```

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001

```
L10           17 S L1
                 E NEUROSERPIN
L11          728 S L2
L12           24 S L3
L13          343 S L5
L14         4326 S L6
L15          171 S L7
L16           16 S L8
L17          372 S L9
                 E NEUROPATHY
L18         5490 S E3
                 E EPILEPSY
L19        10805 S E3-E12
                 E SEIZURE
L20        14562 S E3-E6
                 E HYPOXIA
L21        24801 S E3
                 E STROKE
L22        11880 S E3
L23            0 S L17 AND L18
L24            0 S L17 AND L19
L25            0 S L17 AND L20
L26            0 S L17 AND L21
L27            0 S L17 AND L22
L28            0 S L16 AND L18
L29        25960 S L18 OR L19 OR L20
L30            0 S L29 AND L16
L31            0 S L29 AND L15
L32            4 S L29 AND L14
L33            0 S L29 AND L13
L34            0 S L29 AND L12
L35           30 S L29 AND L11
L36            0 S L29 AND L10
L37          350 S L21 AND L22
L38        36331 S L21 OR L22
L39            4 S L38 AND L10
L40            2 S L38 AND L11
L41            0 S L38 AND L12
L42            1 S L38 AND L13
L43           46 S L38 AND L14
```

=> s l38 and l15

L44 1 L38 AND L15

=> d l44 1 all

L44 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS
AN 132:288782 CA
TI Methods and compositions for treating neurodegenerative diseases using an antagonist or inhibitor of p25
IN Tsai, Li-Huei; Patrick, Gentry N.; Lee, Ming Sum
PA President and Fellows of Harvard College, USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 14
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021550	A2	20000420	WO 1999-US24221	19991013
WO 2000021550	A3	20000727		

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI US 1998-103975 19981013
US 1999-136631 19990527
AB The present invention relates to methods of preventing or treating neurodegenerative diseases, including Alzheimer's disease, by administering an antagonist or inhibitor of p25. In particular, the invention relates to methods of preventing or treating a neurodegenerative disease by administering a calpain antagonist or inhibitor, or a cation (e.g. Ca2+) antagonist or inhibitor, which reduces the truncation or conversion of p35 to p25. Calpeptin and ALLM, inhibitors of a calcium-activated protease (calpain), completely inhibited the conversion of p35 to p25 in calcium-treated mouse brain lysate, indicating that calpain plays an important role in the conversion process.
ST p35 conversion p25 inhibitor neurodegenerative disease; calpain cation inhibitor nervous system agent
IT Parkinson's disease
(Guamanian parkinsonism-dementia; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Nervous system
(Huntington's chorea; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Mental disorder
(Pick's disease; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Nerve
(degeneration, corticobasal; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Mental disorder
(dementia; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Chromosome
(human 17, dementia linked to; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)
IT Anti-Alzheimer's agents

Anti-ischemic agents
Antiparkinsonian agents
Down's syndrome
Nervous system agents
Neurofibrillary tangle
Niemann-Pick disease
Oxidative stress, biological
(inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Brain
Spinal cord
(inhibition of conversion of p35 to p25 in brain and spinal cord for treating neurodegenerative diseases)

IT Nucleic acids
Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of protein p25 for treating neurodegenerative diseases)

IT Brain, disease
Heart, disease
(ischemia; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Muscular dystrophy
(myotonic; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Apoptosis
(neuronal; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Dopamine agonists
(non-ergot DE; inhibition of protein p25 for treating neurodegenerative diseases)

IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process)
(p25; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Proteins, specific or class
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(p35; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Encephalitis
(pan-, subacute sclerosing; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Parkinson's disease
(postencephalic; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Phosphorylation, biological
(protein; redn. of phosphorylation of .tau. protein by p25/cdk5 kinase for treating neurodegenerative diseases)

IT Paralysis
(pseudobulbar; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Nervous system
(sclerosis, lower lateral; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(specific to p25 or cdk5; inhibition of protein p25 for treating neurodegenerative diseases)

IT Brain, disease
(**stroke**; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Multiple sclerosis
(therapeutic agents; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Prion diseases
(with tangles; inhibition of conversion of p35 to p25 for treating neurodegenerative diseases)

IT Transferrins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(.tau.-transferrins, phosphorylation; redn. of phosphorylation of .tau.
protein by p25/cdk5 kinase for treating neurodegenerative diseases)

IT **55123-66-5**, Leupeptin 66701-25-5, E 64 79079-11-1, Calpastatin 88191-84-8, MDL 28170 110044-82-1 110115-07-6 117591-20-5, Calpeptin
158798-83-5, AK 275
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calpain inhibitors for treating neurodegenerative diseases)

IT 7439-95-4, Magnesium, biological studies 7440-70-2, Calcium, biological studies 78990-62-2, Calpain
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calpain or cation inhibitors for treating neurodegenerative diseases)

IT 147014-96-8, Cdk5 kinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(inhibition of deregulation of cdk5 kinase by p25 for treating neurodegenerative diseases)

IT 91374-21-9, Ropinirole 117630-06-5, .omega.-Conotoxin 141429-64-3, SB 201823A 264236-80-8, MkA 01
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of protein p25 for treating neurodegenerative diseases)

IT 9001-66-5, Monoamine oxidase 9012-25-3, Catechol-O-methyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; inhibition of protein p25 for treating neurodegenerative diseases)

```
=> s l38 and l16

L45             0 L38 AND L16

=> s l38 and l17

L46             0 L38 AND L17

=> d his


     (FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

     FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1             11 S NEUROSERPIN
L2              1 S PMSF
L3              1 S APMSF
L4              1 S L3
```

```
L5            5 S ANTIPAIN
L6          170 S ANTITHROMBIN
L7           11 S LEUPEPTIN
L8            9 S DICHLOROCOUMARIN
L9            2 S TLCK

     FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

     FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10          17 S L1
                E NEUROSERPIN
L11         728 S L2
L12          24 S L3
L13         343 S L5
L14        4326 S L6
L15         171 S L7
L16          16 S L8
L17         372 S L9
                E NEUROPATHY
L18        5490 S E3
                E EPILEPSY
L19       10805 S E3-E12
                E SEIZURE
L20       14562 S E3-E6
                E HYPOXIA
L21       24801 S E3
                E STROKE
L22       11880 S E3
L23           0 S L17 AND L18
L24           0 S L17 AND L19
L25           0 S L17 AND L20
L26           0 S L17 AND L21
L27           0 S L17 AND L22
L28           0 S L16 AND L18
L29       25960 S L18 OR L19 OR L20
L30           0 S L29 AND L16
L31           0 S L29 AND L15
L32           4 S L29 AND L14
L33           0 S L29 AND L13
L34           0 S L29 AND L12
L35          30 S L29 AND L11
L36           0 S L29 AND L10
L37         350 S L21 AND L22
L38       36331 S L21 OR L22
L39           4 S L38 AND L10
L40           2 S L38 AND L11
L41           0 S L38 AND L12
L42           1 S L38 AND L13
L43          46 S L38 AND L14
L44           1 S L38 AND L15
L45           0 S L38 AND L16
L46           0 S L38 AND L17

=> e ischema

E1            5     ISCHELIUM/BI
E2          112     ISCHEM/BI
E3            9 --> ISCHEMA/BI
E4            1     ISCHEMAI/BI
E5            2     ISCHEMI/BI
E6        40127     ISCHEMIA/BI
E7            2     ISCHEMIAC/BI
E8            1     ISCHEMIAINDUCED/BI
```

```
E9            3     ISCHEMIAL/BI
E10           2     ISCHEMIALLY/BI
E11           1     ISCHEMIAREPERFUSION/BI
E12          44     ISCHEMIAS/BI

=> s e6

L47      40127 ISCHEMIA/BI

=> s l47 and l10

L48           3 L47 AND L10

=> d l48 1-3


L48  ANSWER 1 OF 3  CA  COPYRIGHT 2001 ACS
AN   133:187780  CA
TI   Neuroserpin reduces cerebral infarct volume and protects neurons from
     ischemia-induced apoptosis
AU   Yepes, Manuel; Sandkvist, Maria; Wong, Mike K. K.; Coleman, Timothy A.;
     Smith, Elizabeth; Cohan, Stanley L.; Lawrence, Daniel A.
CS   Department of Biochemistry, American Red Cross Holland Laboratory,
     Rockville, MD, 20855, USA
SO   Blood (2000), 96(2), 569-576
     CODEN: BLOOAW; ISSN: 0006-4971
PB   American Society of Hematology
DT   Journal
LA   English
RE.CNT  70
RE
(1) Ahn, M; Brain Res 1999, V837, P169 CA
(3) Benveniste, H; J Neurochem 1984, V43, P1369 CA
(5) Calof, A; Neuron 1994, V13, P117 CA
(7) Carroll, P; Development 1994, V120, P3173 CA
(8) Chen, Z; Cell 1997, V91, P917 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 2 OF 3  CA  COPYRIGHT 2001 ACS
AN   131:255873  CA
TI   Transforming growth factor-.beta.1 as a regulator of the serpins/t-PA
axis
     in cerebral ischemia
AU   Docagne, Fabian; Nicole, Olivier; Marti, Hugo H.; MacKenzie, Eric T.;
     Buisson, Alain; Vivien, Denis
CS   Universite de Caen, CNRS UMR 6551, Caen, 14074, Fr.
SO   FASEB J. (1999), 13(11), 1315-1324
     CODEN: FAJOEC; ISSN: 0892-6638
PB   Federation of American Societies for Experimental Biology
DT   Journal
LA   English
RE.CNT  57
RE
(1) Breier, G; Development 1992, V114, P521 CA
(2) Buisson, A; FASEB J 1998, V12, P1683 CA
(3) Buisson, A; Neuropharmacology 1995, V34, P1081 CA
(5) Constam, D; J Immunol 1992, V148, P1404 CA
(6) Cunningham, D; J Cell Biochem 1989, V39, P55 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 3 OF 3  CA  COPYRIGHT 2001 ACS
AN   131:139510  CA
TI   Neuroserpin applications as a pharmaceutical or diagnostic agent
```

IN Sonderegger, Peter; Schrimpf, Sabine Petra; Kruger, Stefan Robert; Osterwalder, Thomas; Stockli, Esther Trudi
PA Switz.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9941381	A1	19990819	WO 1999-IB248	19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9921807	A1	19990830	AU 1999-21807	19990212
PRAI US 1998-23129		19980213		
WO 1999-IB248		19990212		

RE.CNT 6
RE
(1) Coleman, T; WO 9816643 A 1998 CA
(2) Hastings, G; THE JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(52), P33062 CA
(3) Incyte Pharma Inc; WO 9640922 A 1996 CA
(4) Krueger, S; THE JOURNAL OF NEUROSCIENCE 1997, V17(23), P8984 CA
(6) Schrimpf; GENOMICS 1997, V40(1), P55 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l47 and l16

L49 0 L47 AND L16

=> s l47 and l15

L50 3 L47 AND L15

=> d l50 1-3

L50 ANSWER 1 OF 3 CA COPYRIGHT 2001 ACS
AN 132:288782 CA
TI Methods and compositions for treating neurodegenerative diseases using an antagonist or inhibitor of p25
IN Tsai, Li-Huei; Patrick, Gentry N.; Lee, Ming Sum
PA President and Fellows of Harvard College, USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021550	A2	20000420	WO 1999-US24221	19991013
WO 2000021550	A3	20000727		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI US 1998-103975		19981013		

US 1999-136631 19990527

L50 ANSWER 2 OF 3 CA COPYRIGHT 2001 ACS
AN 119:136686 CA
TI Protective effect of the protease inhibitor leupeptin against myocardial stunning
AU Matsumura, Yasushi; Kusuoka, Hideo; Inoue, Michitoshi; Hori, Masatsugu; Kamada, Takenobu
CS Med. Sch., Osaka Univ., Suita, 565, Japan
SO J. Cardiovasc. Pharmacol. (1993), 22(1), 135-42
CODEN: JCPCDT; ISSN: 0160-2446
DT Journal
LA English

L50 ANSWER 3 OF 3 CA COPYRIGHT 2001 ACS
AN 109:236993 CA
TI Carnitine-coupled pharmaceutical agents for site-specific delivery to cardiac and skeletal muscle
IN Stracher, Alfred; Kesner, Leo
PA USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4742081	A	19880503	US 1986-816546	19860106
	US 4866040	A	19890912	US 1987-3888	19870115
	US 5008288	A	19910416	US 1989-347361	19890504
	US 5876747	A	19990302	US 1992-912068	19920708
PRAI	US 1986-816546	19860106			
	US 1987-3888	19870115			
	US 1989-347361	19890504			
	US 1991-638948	19910109			

OS MARPAT 109:236993

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1 11 S NEUROSERPIN
L2 1 S PMSF
L3 1 S APMSF
L4 1 S L3
L5 5 S ANTIPAIN
L6 170 S ANTITHROMBIN
L7 11 S LEUPEPTIN
L8 9 S DICHLOROCOUMARIN
L9 2 S TLCK

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10 17 S L1
E NEUROSERPIN
L11 728 S L2
L12 24 S L3
L13 343 S L5
L14 4326 S L6

```
L15          171 S L7
L16           16 S L8
L17          372 S L9
                 E NEUROPATHY
L18         5490 S E3
                 E EPILEPSY
L19        10805 S E3-E12
                 E SEIZURE
L20        14562 S E3-E6
                 E HYPOXIA
L21        24801 S E3
                 E STROKE
L22        11880 S E3
L23            0 S L17 AND L18
L24            0 S L17 AND L19
L25            0 S L17 AND L20
L26            0 S L17 AND L21
L27            0 S L17 AND L22
L28            0 S L16 AND L18
L29        25960 S L18 OR L19 OR L20
L30            0 S L29 AND L16
L31            0 S L29 AND L15
L32            4 S L29 AND L14
L33            0 S L29 AND L13
L34            0 S L29 AND L12
L35           30 S L29 AND L11
L36            0 S L29 AND L10
L37          350 S L21 AND L22
L38        36331 S L21 OR L22
L39            4 S L38 AND L10
L40            2 S L38 AND L11
L41            0 S L38 AND L12
L42            1 S L38 AND L13
L43           46 S L38 AND L14
L44            1 S L38 AND L15
L45            0 S L38 AND L16
L46            0 S L38 AND L17
                 E ISCHEMA
L47        40127 S E6
L48            3 S L47 AND L10
L49            0 S L47 AND L16
L50            3 S L47 AND L15

=> d l47 and l11

L11 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l47 and l11

L51            3 L47 AND L11

=> d l51 1-3


L51  ANSWER 1 OF 3  CA  COPYRIGHT 2001 ACS
AN   121:99561  CA
TI   Effect of phenylmethylsulfonyl fluoride (PMSF) on brain arachidonic acid
     and extracellular glutamate level in complete cerebral ischemia
     in rats
AU   Tanimura, Hajime
CS   Dep. Neurosurg., Kakegawa Gen. Hosp., Kakegawa, 436, Japan
SO   Brain Nerve (1994), 46(2), 153-7
```



CODEN: BRNED8; ISSN: 0006-8969
DT Journal
LA Japanese

L51 ANSWER 2 OF 3 CA COPYRIGHT 2001 ACS
AN 117:168825 CA
TI A phospholipase C inhibitor ameliorates postischemic neuronal damage in rats
AU Umemura, Atsushi; Mabe, Hideo; Nagai, Hajime
CS Med. Sch., Nagoya City Univ., Nagoya, Japan
SO Stroke (Dallas) (1992), 23(8), 1163-6
CODEN: SJCCA7; ISSN: 0039-2499
DT Journal
LA English

L51 ANSWER 3 OF 3 CA COPYRIGHT 2001 ACS
AN 103:206103 CA
TI Protection by acyl-carnitines and phenylmethylsulfonyl fluoride of rat heart subjected to **ischemia** and reperfusion
AU Huelsmann, W. C.; Dubelaar, M. L.; Lamers, J. M. J.; Maccari, F.
CS Med. Fac., Erasmus Univ., Rotterdam, 3000 DR, Neth.
SO Biochim. Biophys. Acta (1985), 847(1), 62-6
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English

=> d 151 1 2 3 all

L51 ANSWER 1 OF 3 CA COPYRIGHT 2001 ACS
AN 121:99561 CA
TI Effect of phenylmethylsulfonyl fluoride (PMSF) on brain arachidonic acid and extracellular glutamate level in complete cerebral **ischemia** in rats
AU Tanimura, Hajime
CS Dep. Neurosurg., Kakegawa Gen. Hosp., Kakegawa, 436, Japan
SO Brain Nerve (1994), 46(2), 153-7
CODEN: BRNED8; ISSN: 0006-8969
DT Journal
LA Japanese
CC 1-11 (Pharmacology)
AB Complete cerebral **ischemia** was induced in rats by decapitation. Tissue concns. of free arachidonic acid and extracellular levels of glutamate were measured in the striatum after the ischemic insult. PMSF inhibited arachidonic acid release during the 1st 4 min of **ischemia**. PMSF also prevented the **ischemia**-induced rise in extracellular glutamate during the 1st 4 min of **ischemia**. Since it is known that acetylcholine inhibits glutamate release, these results suggest that PMSF inhibits acetylcholinesterase activity in the early stage of complete cerebral **ischemia** and thereby inhibits the **ischemia**-induced increase of extracellular glutamate; the inhibition of arachidonic acid release may be secondary to the inhibition of glutamate receptors rather than to an inhibition of phospholipase C activity.
ST brain **ischemia** phenylmethylsulfonyl fluoride; arachidonate metab
brain **ischemia** phenylmethylsulfonyl fluoride; glutamate metab
brain **ischemia** phenylmethylsulfonyl fluoride
IT Brain, disease
(**ischemia**, arachidonic acid and glutamic acid metab. in, phenylmethylsulfonyl fluoride effect on)
IT **329-98-6**, Phenylmethylsulfonyl fluoride
RL: BIOL (Biological study)

(arachidonic acid and glutamic acid metab. by brain in **ischemia** response to)

IT 56-86-0, Glutamic acid, biological studies 506-32-1, Arachidonic acid
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(metab. of, by brain in **ischemia**, phenylmethylsulfonyl fluoride effect on)

L51 ANSWER 2 OF 3 CA COPYRIGHT 2001 ACS
AN 117:168825 CA
TI A phospholipase C inhibitor ameliorates postischemic neuronal damage in rats
AU Umemura, Atsushi; Mabe, Hideo; Nagai, Hajime
CS Med. Sch., Nagoya City Univ., Nagoya, Japan
SO Stroke (Dallas) (1992), 23(8), 1163-6
CODEN: SJCCA7; ISSN: 0039-2499
DT Journal
LA English
CC 14-10 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
AB Calcium-induced neuronal damage may occur in brain **ischemia**. Phospholipase C catalyzes the phosphodiester bond cleavage of phosphatidylinositol. The cleavage of phosphatidylinositol 4,5-bisphosphate by phospholipase C yields 1,4,5-inositol trisphosphate, which mediates the intracellular release of calcium, and 1,2-diacylglycerol, which is an activator of protein kinase C. The effects of phenylmethylsulfonylfluoride, a phospholipase C inhibitor, on delayed neuronal damage after a transient 20-min forebrain **ischemia** were studied in the brain hippocampal CA1 subfield in rats to assess the role of phospholipase C in postischemic neuronal damage. The neuronal d. in the CA1 subfield was detd. 7 days after reperfusion. In the vehicle treatment group, the neuronal d. was 51 cells/mm of length. The neuronal densities in the 50 and 100-mg/kg phenylmethylsulfonylfluoride pretreatment groups and the 100-mg/kg phenylmethylsulfonylfluoride posttreatment group were 99, 150, and 143 cells/mm, resp. Thus, activation of phospholipase C has an important role
in the postischemic delayed neuronal damage.
ST brain **ischemia** neuron damage phospholipase C
IT Brain, disease
(**ischemia**, phospholipase C in pathogenesis of neuron damage in)
IT 9001-86-9, Phospholipase C
RL: BIOL (Biological study)
(in brain ischemic neuron damage pathogenesis)
IT **329-98-6**, Phenylmethylsulfonylfluoride
RL: BIOL (Biological study)
(phospholipase C inhibition by, brain neuron ischemic damage decrease by)

L51 ANSWER 3 OF 3 CA COPYRIGHT 2001 ACS
AN 103:206103 CA
TI Protection by acyl-carnitines and phenylmethylsulfonyl fluoride of rat heart subjected to **ischemia** and reperfusion
AU Huelsmann, W. C.; Dubelaar, M. L.; Lamers, J. M. J.; Maccari, F.
CS Med. Fac., Erasmus Univ., Rotterdam, 3000 DR, Neth.
SO Biochim. Biophys. Acta (1985), 847(1), 62-6
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English
CC 1-8 (Pharmacology)
AB Perfusion of rat hearts according to the Langendorff technique with micromolar concns. of palmitoylcarnitine [1935-18-8] or millimolar concns. of phenylmethylsulfonyl fluoride [**329-98-6**] protects

the heart from deterioration by reperfusion after total **ischemia**. This is based on the retention of the cytosolic enzymes detd. (lactate dehydrogenase, glycogen phosphorylase and glycogen synthase) and of myoglobin, as well as on the resumption of contractile activity. Palmitoylcarnitine, like phenylmethylsulfonyl fluoride, could protect through plasma membrane stabilization, since more hydrophilic compds. had no effect.

ST acylcarnitine phenylmethylsulfonyl fluoride heart **ischemia**

IT Hydrophilicity
(of acylcarnitines, heart protection after **ischemia** and reperfusion in relation to)

IT Heart, disease or disorder
(**ischemia**, damage from reperfusion after, acylcarnitines and phenylmethylsulfonyl fluoride protection from)

IT **329-98-6** 541-14-0 541-15-1 541-15-1D, acyl derivs.
1935-18-8 17298-37-2 25243-95-2 76932-34-8
RL: BIOL (Biological study)
(heart protection from, in **ischemia** and reperfusion)

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001

```
L1            11 S NEUROSERPIN
L2             1 S PMSF
L3             1 S APMSF
L4             1 S L3
L5             5 S ANTIPAIN
L6           170 S ANTITHROMBIN
L7            11 S LEUPEPTIN
L8             9 S DICHLOROCOUMARIN
L9             2 S TLCK
```

FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001

```
L10           17 S L1
                 E NEUROSERPIN
L11          728 S L2
L12           24 S L3
L13          343 S L5
L14         4326 S L6
L15          171 S L7
L16           16 S L8
L17          372 S L9
                 E NEUROPATHY
L18         5490 S E3
                 E EPILEPSY
L19        10805 S E3-E12
                 E SEIZURE
L20        14562 S E3-E6
                 E HYPOXIA
L21        24801 S E3
                 E STROKE
L22        11880 S E3
L23            0 S L17 AND L18
L24            0 S L17 AND L19
L25            0 S L17 AND L20
L26            0 S L17 AND L21
L27            0 S L17 AND L22
```

```
L28            0 S L16 AND L18
L29        25960 S L18 OR L19 OR L20
L30            0 S L29 AND L16
L31            0 S L29 AND L15
L32            4 S L29 AND L14
L33            0 S L29 AND L13
L34            0 S L29 AND L12
L35           30 S L29 AND L11
L36            0 S L29 AND L10
L37          350 S L21 AND L22
L38        36331 S L21 OR L22
L39            4 S L38 AND L10
L40            2 S L38 AND L11
L41            0 S L38 AND L12
L42            1 S L38 AND L13
L43           46 S L38 AND L14
L44            1 S L38 AND L15
L45            0 S L38 AND L16
L46            0 S L38 AND L17
                 E ISCHEMA
L47        40127 S E6
L48            3 S L47 AND L10
L49            0 S L47 AND L16
L50            3 S L47 AND L15
L51            3 S L47 AND L11

=> s l47 and l12

L52            0 L47 AND L12

=> s l47 and l13

L53            1 L47 AND L13

=> s l53 1

MISSING OPERATOR L53 1
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l53 1


L53 ANSWER 1 OF 1  CA  COPYRIGHT 2001 ACS
AN   99:205847  CA
TI   Role of cellular proteinases in acute myocardial infarction.  I.
     Proteolysis in nonischemic and ischemic rat myocardium and the effects of
     antipain, leupeptin, pepstatin and chymostatin administered in vivo
AU   Bolli, Roberto; Cannon, Richard O.; Speir, Edith; Goldstein, Robert E.;
     Epstein, Stephen E.
CS   Sect. Exp. Phys. Pharmacol., Natl. Heart, Lung, Blood Inst., Bethesda,
MD,
     USA
SO   J. Am. Coll. Cardiol. (1983), 2(4), 671-80
     CODEN: JACCDI; ISSN: 0735-1097
DT   Journal
LA   English


=> d l53 1 all


L53  ANSWER 1 OF 1  CA  COPYRIGHT 2001 ACS
```

AN 99:205847 CA
TI Role of cellular proteinases in acute myocardial infarction. I. Proteolysis in nonischemic and ischemic rat myocardium and the effects of antipain, leupeptin, pepstatin and chymostatin administered in vivo
AU Bolli, Roberto; Cannon, Richard O.; Speir, Edith; Goldstein, Robert E.; Epstein, Stephen E.
CS Sect. Exp. Phys. Pharmacol., Natl. Heart, Lung, Blood Inst., Bethesda, MD, USA
SO J. Am. Coll. Cardiol. (1983), 2(4), 671-80
CODEN: JACCDI; ISSN: 0735-1097
DT Journal
LA English
CC 1-8 (Pharmacology)
Section cross-reference(s): 14
AB To test the hypothesis that cellular proteinase [9001-92-7] contribute to ischemic myocellular death, measurements were made of tyrosine release (an index of overall proteolysis) from incubated slices of nonischemic and ischemic myocardium obtained at various times after coronary artery occlusion in rats. Proteolysis failed to increase in ischemic myocardium throughout the first 24 h of occlusion, when irreversible damage develops, indicating that cellular proteinases do not undergo generalized activation in this phase. The ability of the proteinase inhibitors antipain [**37691-11-5**], leupeptin, pepstatin [39324-30-6], and chymostatin [9076-44-2], given in vivo, to interfere with proteolysis in ischemic myocardium was also evaluated. Leupeptin (10 or 40 mg/kg) inhibited proteolysis in a dose-related fashion (-49 and -72%, resp.). Antipain (20 mg/kg) decreased protein breakdown by 60%. The combination of antipain (20 mg/kg), leupeptin (40 mg/kg); and pepstatin 5 mg/kg) suppressed proteolysis almost completely at both 15 min (-88%) and at 6 h (-72%) of **ischemia**, i.e., throughout the development of irreversible injury. These results demonstrate that whatever proteolysis is occurring during acute myocardial infarction is largely mediated by cathepsins A, B, D, L and H and by calcium-activated neutral protease.
ST heart infarction proteinase inhibitor
IT Leupeptins
RL: BIOL (Biological study)
(proteinase inhibition by, in myocardial infarction)
IT Proteins
RL: BIOL (Biological study)
(proteolysis of, in myocardial infarction, proteinase inhibition in relation to)
IT Heart, disease or disorder
(infarction, proteolysis in, proteinase inhibition in relation to)
IT 9001-92-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, proteolysis in myocardial infarction response to)
IT 9076-44-2 **37691-11-5** 39324-30-6
RL: BIOL (Biological study)
(proteinase inhibition by, in myocardial infarction)
IT 9004-08-4
RL: BIOL (Biological study)
(proteolysis during acute myocardial infarction in relation to)

=> d his

```
      (FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

      FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1           11 S NEUROSERPIN
L2            1 S PMSF
L3            1 S APMSF
L4            1 S L3
L5            5 S ANTIPAIN
L6          170 S ANTITHROMBIN
L7           11 S LEUPEPTIN
L8            9 S DICHLOROCOUMARIN
L9            2 S TLCK

      FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

      FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10          17 S L1
                E NEUROSERPIN
L11         728 S L2
L12          24 S L3
L13         343 S L5
L14        4326 S L6
L15         171 S L7
L16          16 S L8
L17         372 S L9
                E NEUROPATHY
L18        5490 S E3
                E EPILEPSY
L19       10805 S E3-E12
                E SEIZURE
L20       14562 S E3-E6
                E HYPOXIA
L21       24801 S E3
                E STROKE
L22       11880 S E3
L23           0 S L17 AND L18
L24           0 S L17 AND L19
L25           0 S L17 AND L20
L26           0 S L17 AND L21
L27           0 S L17 AND L22
L28           0 S L16 AND L18
L29       25960 S L18 OR L19 OR L20
L30           0 S L29 AND L16
L31           0 S L29 AND L15
L32           4 S L29 AND L14
L33           0 S L29 AND L13
L34           0 S L29 AND L12
L35          30 S L29 AND L11
L36           0 S L29 AND L10
L37         350 S L21 AND L22
L38       36331 S L21 OR L22
L39           4 S L38 AND L10
L40           2 S L38 AND L11
L41           0 S L38 AND L12
L42           1 S L38 AND L13
L43          46 S L38 AND L14
L44           1 S L38 AND L15
L45           0 S L38 AND L16
L46           0 S L38 AND L17
                E ISCHEMA
L47       40127 S E6
L48           3 S L47 AND L10
L49           0 S L47 AND L16
```

```
L50             3 S L47 AND L15
L51             3 S L47 AND L11
L52             0 S L47 AND L12
L53             1 S L47 AND L13

=> d l47 and l14

L14 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l47 and l14

L54            52 L47 AND L14

=> s his

L55        28898 HIS

=> d his


     (FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

     FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1              11 S NEUROSERPIN
L2               1 S PMSF
L3               1 S APMSF
L4               1 S L3
L5               5 S ANTIPAIN
L6             170 S ANTITHROMBIN
L7              11 S LEUPEPTIN
L8               9 S DICHLOROCOUMARIN
L9               2 S TLCK

     FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

     FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10             17 S L1
                   E NEUROSERPIN
L11            728 S L2
L12             24 S L3
L13            343 S L5
L14           4326 S L6
L15            171 S L7
L16             16 S L8
L17            372 S L9
                   E NEUROPATHY
L18           5490 S E3
                   E EPILEPSY
L19          10805 S E3-E12
                   E SEIZURE
L20          14562 S E3-E6
                   E HYPOXIA
L21          24801 S E3
                   E STROKE
L22          11880 S E3
L23              0 S L17 AND L18
L24              0 S L17 AND L19
L25              0 S L17 AND L20
L26              0 S L17 AND L21
L27              0 S L17 AND L22
L28              0 S L16 AND L18
L29          25960 S L18 OR L19 OR L20
```

```
L30             0 S L29 AND L16
L31             0 S L29 AND L15
L32             4 S L29 AND L14
L33             0 S L29 AND L13
L34             0 S L29 AND L12
L35            30 S L29 AND L11
L36             0 S L29 AND L10
L37           350 S L21 AND L22
L38         36331 S L21 OR L22
L39             4 S L38 AND L10
L40             2 S L38 AND L11
L41             0 S L38 AND L12
L42             1 S L38 AND L13
L43            46 S L38 AND L14
L44             1 S L38 AND L15
L45             0 S L38 AND L16
L46             0 S L38 AND L17
                  E ISCHEMA
L47         40127 S E6
L48             3 S L47 AND L10
L49             0 S L47 AND L16
L50             3 S L47 AND L15
L51             3 S L47 AND L11
L52             0 S L47 AND L12
L53             1 S L47 AND L13
L54            52 S L47 AND L14
L55         28898 S HIS

=> s l54 not l43

L56            47 L54 NOT L43

=> d l56 10-47


L56  ANSWER 10 OF 47  CA  COPYRIGHT 2001 ACS
AN   131:295340  CA
TI   Effects of a novel mac-1 inhibitor, NPC 15669, on hemostatic parameters
     during preconditioned myocardial infarction
AU   Serebruany, Victor L.; Yurovsky, Vladimir V.; Gurbel, Paul A.
CS   Sinai Center for Thrombosis Research, University of Maryland School of
     Medicine, Baltimore, MD, 21201, USA
SO   Life Sci. (1999), 65(14), 1503-1513
     CODEN: LIFSAK; ISSN: 0024-3205
PB   Elsevier Science Inc.
DT   Journal
LA   English
RE.CNT  36
RE
(1) Bastida, E; Blood 1987, V70, P1437 CA
(2) Bennett, R; Arteriosc Thromb 1993, V13, P360 CA
(5) Cho, P; J Surg Res 1993, V54, P486 CA
(6) Corbi, A; J Biol Chem 1988, V263, P12403 CA
(9) D'Angelo, A; Thromb Res 1994, V75, P133 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56  ANSWER 11 OF 47  CA  COPYRIGHT 2001 ACS
AN   131:27699  CA
TI   Antithrombin III treatment improves parameters of acute inflammation in a
     highly histoincompatible model of rat lung allograft rejection
AU   Okada, Yoshinori; Zuo, Xiao-Jing; Marchevsky, Alberto M.; Nicolaidou,
     Electra; Toyoda, Mieko; Matloff, Jack M.; Jordan, Stanley C.
CS   Department of Cardiothoracic Surgery, The Cedars Sinai Medical Center
```

Burns and Allen Research Institute, UCLA School of Medicine, Los Angeles, CA, 90048, USA
SO Transplantation (1999), 67(4), 526-528
CODEN: TRPLAU; ISSN: 0041-1337
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 13
RE
(2) Altieri, D; Cell Immunol 1994, V155(2), P372 CA
(8) Matsumura, Y; Transplantation 1995, V59, P551 CA
(10) Okajima, K; Semin Thromb Hemost 1998, V24(1), P27 CA
(12) Takeshita, K; Transplant Proc 1996, V28, P631 CA
(13) Uchiba, M; Am J Physiol 1996, V270, PL921 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 12 OF 47 CA COPYRIGHT 2001 ACS
AN 131:13277 CA
TI Prevention of the endothelial cell injury by physiological anticoagulants.
The mechanisms and therapeutic implications
AU Okajima, Kenji
CS Sch. Med., Kumamoto Univ., Kumamoto, 860-8556, Japan
SO Seibutsu Shiryo Bunseki (1998), 21(4), 243-248
CODEN: SSBUEL; ISSN: 0913-3763
PB Seibutsu Shiryo Bunseki Kagakkai
DT Journal; General Review
LA Japanese

L56 ANSWER 13 OF 47 CA COPYRIGHT 2001 ACS
AN 130:294938 CA
TI The effect of tissue factor pathway inhibitor on hepatic ischemic reperfusion injury of the rat
AU Yoshimura, Norio; Kobayashi, Yosifumi; Nakamura, Kenji; Yamagishi, Hisakazu; Oka, Takahiro
CS Second Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto City, 602, Japan
SO Transplantation (1999), 67(1), 45-53
CODEN: TRPLAU; ISSN: 0041-1337
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 46
RE
(1) Archipoff, G; Biochem J 1991, V273, P679 CA
(2) Bajaj, M; Proc Natl Acad Sci USA 1990, V87, P8869 CA
(4) Brand, K; Mol Cell Biol 1991, V11, P4732 CA
(6) Brisseau, G; Blood 1995, V85, P1025 CA
(8) Colucci, M; J Clin Invest 1983, V71, P1893 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 14 OF 47 CA COPYRIGHT 2001 ACS
AN 130:246619 CA
TI Treatment of severe head injury with ahylysantifarctum
AU Liu, Weiping; Zhang, Xiang; Yi, Shengyu; Gu, Jianwen; Song, Tao
CS Department of Neurosurgery, 4th Military Medical University Xijing Hospital, Xi'an, 710033, Peop. Rep. China
SO Disi Junyi Daxue Xuebao (1998), 19(5), 529-531
CODEN: DJDXEG; ISSN: 1000-2790
PB Disi Junyi Daxue Xuebao Bianjibu
DT Journal
LA Chinese

L56 ANSWER 15 OF 47 CA COPYRIGHT 2001 ACS
AN 130:232253 CA
TI Antithrombin III prevents 60 min warm intestinal **ischemia** reperfusion injury in rats
AU Ozden, Akin; Tetik, Cihat; Bilgihan, Ayse; Calli, Nese; Bostanci, Birol; Yis, Ozgur; Duzcan, Ender
CS Medical School, Dep. Surgery, Pamukkale Univ., Denizli, Turk.
SO Res. Exp. Med. (1999), 198(5), 237-246
CODEN: REXMAS; ISSN: 0300-9130
PB Springer-Verlag
DT Journal
LA English
RE.CNT 30
RE
(7) Grisham, M; Am J Physiol 1986, V251, PG567 CA
(9) Hisama, N; Dig Dis Sci 1996, V41, P1481 CA
(10) Kirchhofer, D; Blood 1993, V81, P2050 CA
(11) Li, X; Transplantation Proc 1994, V26, P2423 CA
(12) Matsutani, T; J Surg Res 1998, V79, P158 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 16 OF 47 CA COPYRIGHT 2001 ACS
AN 130:176992 CA
TI The anti-inflammatory properties of antithrombin III: new therapeutic implications
AU Okajima, Kenji; Uchiba, Mitsuhiro
CS Department of Laboratory Medicine, Kumamoto University School of Medicine,
Kumamoto, 860, Japan
SO Semin. Thromb. Hemostasis (1998), 24(1), 27-32
CODEN: STHMBV; ISSN: 0094-6176
PB Thieme Medical Publishers, Inc.
DT Journal; General Review
LA English
RE.CNT 35
RE
(1) Atalla, S; Transplantation 1985, V40, P584 CA
(4) Coalson, J; Circ Shock 1978, V5, P423 CA
(5) Eisenhut, T; Immunopharmacol 1993, V26, P259 CA
(8) Gordon, J; Br J Pharmacol 1983, V80, P179 CA
(9) Harada, N; The Immune Consequence of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches 1997, P625 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 17 OF 47 CA COPYRIGHT 2001 ACS
AN 130:61081 CA
TI Compositions for treating and preventing arterial thrombosis and use of a factor Xa inhibitor alone or combined with a platelet aggregation inhibitor
IN Bernat, Andre; Herbert, Jean-Marc; Petitou, Maurice; Van Amsterdam, Ronald
PA Sanofi, Fr.; Akzo Nobel N.V.
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9856365	A1	19981217	WO 1998-FR1172	19980609

W: AU, BR, BY, CA, CN, CZ, EE, HU, ID, IL, IS, JP, KR, LK, LT, LV, MX, NO, NZ, PL, RU, SG, SI, SK, TR, UA, US, VN, YU
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE
FR 2764511 A1 19981218 FR 1997-7368 19970613
FR 2764511 B1 20000908
AU 9879246 A1 19981230 AU 1998-79246 19980609
AU 728826 B2 20010118
EP 986376 A1 20000322 EP 1998-929521 19980609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
BR 9810520 A 20000919 BR 1998-10520 19980609
ZA 9805137 A 19990107 ZA 1998-5137 19980612
NO 9906137 A 20000214 NO 1999-6137 19991210
PRAI FR 1997-7368 19970613
WO 1998-FR1172 19980609
RE.CNT 21
RE
(1) Bernat; Fibrinolysis 1996, V10(3), P151 CA
(2) Cadroy, Y; Thrombosis and Haemostasis V70(4), P631 CA
(3) Choay; EP 0138632 A 1985 CA
(4) Daiichi Seiyaku Co; EP 0540051 A 1993 CA
(7) Herault; Blood Coagul Fibrinolysis 1997, V8(3), P206 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 18 OF 47 CA COPYRIGHT 2001 ACS
AN 129:342251 CA
TI Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty
AU Alaigh, Poonam; Hoffman, Carol J.; Korlipara, Giridhar; Neuroth, Arlene; Dervan, John P.; Lawson, William E.; Hultin, Mae B.
CS Department of Medicine, State University at New York at Stony Brook, NY, USA
SO Arterioscler., Thromb., Vasc. Biol. (1998), 18(8), 1281-1286
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English

L56 ANSWER 19 OF 47 CA COPYRIGHT 2001 ACS
AN 129:270382 CA
TI Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease
AU Prisco, D.; Paniccia, R.; Bandinelli, B.; Gori, A. M.; Attanasio, M.; Giusti, B.; Comeglio, M.; Abbate, R.; Gensini, G. F.; Neri Serneri, G. G.
CS Inst. Clinica Medica Generale Cardiologia, Univ. Florence, Florence, I-50134, Italy
SO Int. J. Clin. Lab. Res. (1998), 28(3), 170-173
CODEN: ICLREA; ISSN: 0940-5437
PB Springer-Verlag
DT Journal
LA English

L56 ANSWER 20 OF 47 CA COPYRIGHT 2001 ACS
AN 129:270298 CA
TI Antithrombin III attenuates **ischemia**/reperfusion injury of rat liver by inhibiting leukocyte activation
AU Harada, N.; Okajima, K.; Kushimoto, S.; Isobe, H.; Uchiba, M.; Murakami, K.; Tanaka, K.; Okabe, H.
CS Department of Emergency and Critical Care Medicine, Fukuoka University, Fukuoka, Japan
SO Immune Consequences Trauma, Shock Sepsis, Int. Congr., 4th (1997), 625-630. Editor(s): Faist, Eugen. Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 66MUAY
DT Conference

LA English

L56 ANSWER 21 OF 47 CA COPYRIGHT 2001 ACS
AN 129:183693 CA
TI Antithrombin and **ischemia**/reperfusion
AU Woodman, Richard C.; Ostrovsky, Lena; Teoh, Diane; Payne, Derrice; Poon, Man-Chiu; Kubes, Paul
CS Immunology Research Group, University of Calgary, Calgary, AB, T2N 4N1, Can.
SO Blood Coagulation Fibrinolysis (1998), 9(Suppl. 2, Potential Applications of Antithrombin Concentrate in Systemic Inflammatory Disorders), S7-S15
CODEN: BLFIE7; ISSN: 0957-5235
PB Lippincott-Raven Publishers
DT Journal; General Review
LA English

L56 ANSWER 22 OF 47 CA COPYRIGHT 2001 ACS
AN 129:131043 CA
TI New aspects of the antiinflammatory effect of AT III. Reduction of the reperfusion damage after warm hepatic **ischemia**
AU Maksan, Sasa-Marcel; Gebhard, M. M.; Maksan, M.-O.; Herfarth, C.; Klar, E.
CS Chirurgische Klinik, Abteilung Experimentelle Chirurgie, Universitaet Heidelberg, Heidelberg, D-69120, Germany
SO Chir. Forum Exp. Klin. Forsch. (1998) 383-385
CODEN: CFEKA7; ISSN: 0303-6227
PB Springer-Verlag
DT Journal
LA German

L56 ANSWER 23 OF 47 CA COPYRIGHT 2001 ACS
AN 128:191142 CA
TI Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients
AU Falciani, Michela; Gori, Anna Maria; Fedi, Sandra; Chiarugi, Ludia; Simonetti, Ignazio; Dabizzi, Roberto Piero; Prisco, Domenico; Pepe, Guglielmina; Abbate, Rosanna; Gensini, Gian Franco; Neri Serneri, Gian Gastone
CS Istituto Clinica Medica Generale Cardiologia, University Florence, Florence, I-50134, Italy
SO Thromb. Haemostasis (1998), 79(3), 495-499
CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal
LA English

L56 ANSWER 24 OF 47 CA COPYRIGHT 2001 ACS
AN 127:326191 CA
TI Antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion
AU Ostrovsky, Lena; Woodman, Richard C.; Payne, Derrice; Teoh, Diane; Kubes, Paul
CS Department of Physiology and Biophysics, University of Calgary, Calgary, AB, T2N 4N1, Can.
SO Circulation (1997), 96(7), 2302-2310
CODEN: CIRCAZ; ISSN: 0009-7322
PB American Heart Association
DT Journal
LA English

L56 ANSWER 25 OF 47 CA COPYRIGHT 2001 ACS
AN 127:189106 CA
TI Sinusoidal flow block after warm **ischemia** in rats with

diet-induced fatty liver
AU Hakamada, Kenichi; Sasaki, Mutsuo; Takahashi, Katsuro; Umehara, Yutaka; Konn, Mitsuru
CS Second Department of Surgery, Hirosaki University School of Medicine, Hirosaki, 036, Japan
SO J. Surg. Res. (1997), 70(1), 12-20
CODEN: JSGRA2; ISSN: 0022-4804
PB Academic
DT Journal
LA English

L56 ANSWER 26 OF 47 CA COPYRIGHT 2001 ACS
AN 127:39825 CA
TI Human antithrombin III for treatment of ischemic reperfusion-related liver
damage and compositions containing human antithrombin III
IN Okajima, Kenji; Kushimoto, Shigeki
PA Green Cross Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09110718	A2	19970428	JP 1995-266829	19951016

L56 ANSWER 27 OF 47 CA COPYRIGHT 2001 ACS
AN 126:809 CA
TI Serial changes of natural antithrombotics during myocardial **ischemia**-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
AU Serebruany, V. L.; Herzog, W. R.; Gurbel, P. A.
CS Union Memorial Hospital, Heart Associates Research and Education Foundation, Baltimore, MD, 21218, USA
SO Blood Coagulation Fibrinolysis (1996), 7(6), 632-640
CODEN: BLFIE7; ISSN: 0957-5235
PB Rapid Science Publishers
DT Journal
LA English

L56 ANSWER 28 OF 47 CA COPYRIGHT 2001 ACS
AN 125:339091 CA
TI Pharmaceutical compositions containing human antithrombin-III for shock-induced gastric mucosa disorders
IN Okajima, Kenji; Kushimoto, Shigeki
PA Green Cross Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08245419	A2	19960924	JP 1995-45748	19950306

L56 ANSWER 29 OF 47 CA COPYRIGHT 2001 ACS
AN 125:292706 CA
TI Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine
AU Serebruany, Victor L.; Solomon, Scott R.; Edenbaum, Lisa R.; Herzog, William R.; Gurbel, Paul A.
CS Heart Associated Res. Education Foundation, Union Memorial Hospital,

Baltimore, MD, 21218, USA
SO Pharmacology (1996), 53(2), 87-97
CODEN: PHMGBN; ISSN: 0031-7012
DT Journal
LA English

L56 ANSWER 30 OF 47 CA COPYRIGHT 2001 ACS
AN 125:265930 CA
TI The effects of breviscapin on AT-III activity, tPA and PAI in dogs during acute myocardial **ischemia**
AU Sheng, Jing; Xu, Jimin; Yang, Juxian; Huang, Zhenhua; Wang, Jian; Xu, Weiren
CS Ninth People's Hospital, SSMU, Shanghai, 200011, Peop. Rep. China
SO J. Shanghai Second Med. Univ. (1995), 9(2), 69-73
CODEN: JSSUE7; ISSN: 1001-6686
DT Journal
LA English

L56 ANSWER 31 OF 47 CA COPYRIGHT 2001 ACS
AN 125:158640 CA
TI New clinical uses for human-derived antithrombin III
IN Okajima, Kenji; Taoka, Juji
PA Green Cross Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08169845	A2	19960702	JP 1995-7731	19950120
PRAI	JP 1994-5131	19940121			
	JP 1994-50813	19940322			
	JP 1994-256508	19941021			

L56 ANSWER 32 OF 47 CA COPYRIGHT 2001 ACS
AN 125:104730 CA
TI The effects of Breviscapine on AT-III activity, tPA and PAI in dogs during
acute myocardial **ischemia**
AU Zhao, Peiqi; Xu, Jimin; Sheng, Jing; Yang, Juxiang; Huang, Zhenghua; Wang,
Jian
CS Cardiovascular Research Division, Ninth People's Hospital, Shanghai Second
Medical University, Shanghai, 200011, Peop. Rep. China
SO Shanghai Dier Yike Daxue Xuebao (1996), 16(1), 26-28
CODEN: SDDXE3; ISSN: 0258-5898
DT Journal
LA Chinese

L56 ANSWER 33 OF 47 CA COPYRIGHT 2001 ACS
AN 124:114295 CA
TI Abnormalities in oxygenation, coagulation, and fibrinolysis in colonic blood of horses with experimentally induced strangulation obstruction
AU Kawcak, C. E.; Baxter, G. M.; Getzy, D. M.; Stashak, T. S.; Chapman, P. L.
CS College of Natural Sciences, Colorado State University, Fort Collins, CO, 80523, USA
SO Am. J. Vet. Res. (1995), Volume Date 1995, 56(12), 1642-50
CODEN: AJVRAH; ISSN: 0002-9645
DT Journal
LA English

L56 ANSWER 34 OF 47 CA COPYRIGHT 2001 ACS
AN 121:252796 CA
TI Prothrombin fragment F1 + 2: correlations with cardiovascular risk factors
AU Rugman, F. P.; Jenkins, J. A.; Duguid, J. K.; Maggs, P. Bolton; Hay, C. R.
M.
CS University Department of Haematology, Royal Liverpool Hospital, Liverpool,
L7 3BX, UK
SO Blood Coagulation Fibrinolysis (1994), 5(3), 335-40
CODEN: BLFIE7; ISSN: 0957-5235
DT Journal
LA English

L56 ANSWER 35 OF 47 CA COPYRIGHT 2001 ACS
AN 121:103160 CA
TI Artificial ultraviolet whole-body radiation does not modify serum lipoprotein, plasma fibrinogen, plasminogen or antithrombin III concentrations in post-myocardial infarction patients
AU Clark, Peter; Cockburn, Forrester; Cowan, Robert A.; Czapla, Krystyna; Dunnigan, Matthew G.; Farish, Elizabeth; Hughes, Elaine
CS Medical Division, Departments of Biochemistry and Physiotherapy, Stobhill General Hospital, Glasgow, G21 3UW, UK
SO Atherosclerosis (Shannon, Irel.) (1994), 107(1), 65-9
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

L56 ANSWER 36 OF 47 CA COPYRIGHT 2001 ACS
AN 121:80020 CA
TI Protein S and protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo thrombin activity
AU D'Angelo, Armando; Gerosa, Stefano; Digano, Silvana; Angelo, Silvana Vigano; Mailhac, Alessandra; Colombo, Alessandro; Agazzi, Alberto; Mazzola, Giuseppina; Chierchia, Sergio
CS Coagulation Service and Department of Cardiology, I.R.C.C.S. H S.Raffaele,
Milan, 20132, Italy
SO Thromb. Res. (1994), 75(2), 133-42
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L56 ANSWER 37 OF 47 CA COPYRIGHT 2001 ACS
AN 118:165910 CA
TI Evaluation of endothelial anticoagulant function with venoocclusive test
AU Zateyshchikov, D. A.; Dobrovolsky, A. B.; Averkov, O. V.; Storozhilova, A.
N.; Panchenko, E. P.; Bonnet, J.; Grattsiansky, N. A.
CS Cent. Atherosclerosis, Inst. Phys. Chem. Med., Moscow, Russia
SO Byull. Eksp. Biol. Med. (1992), 114(12), 605-8
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian

L56 ANSWER 38 OF 47 CA COPYRIGHT 2001 ACS
AN 112:116350 CA
TI Antithrombin III and procoagulant activity: sex differences and effects of the menopause
AU Meade, T. W.; Dyer, Sandra; Howarth, D. J.; Imeson, J. D.; Stirling,

Yvonne
CS MRC Epidemiol. Med. Care Unit, Northwick Park Hosp., Harrow/Middlesex, UK
SO Br. J. Haematol. (1990), 74(1), 77-81
CODEN: BJHEAL; ISSN: 0007-1048
DT Journal
LA English

L56 ANSWER 39 OF 47 CA COPYRIGHT 2001 ACS
AN 110:229535 CA
TI Serum lipids and platelet functions in ischemic cerebrovascular diseases
AU Takeuchi, Megumi; Uchiyama, Sinichiro; Kobayashi, Itsuro; Takemiya, Toshiko; Maruyama, Shoichi
CS Neurol. Inst., Tokyo Women's Med. Coll., Tokyo, 162, Japan
SO Tokyo Joshi Ika Daigaku Zasshi (1989), 59(3), 177-83
CODEN: TJIZAF; ISSN: 0040-9022
DT Journal
LA Japanese

L56 ANSWER 40 OF 47 CA COPYRIGHT 2001 ACS
AN 110:205380 CA
TI Effect of intracisternal antithrombin III on subarachnoid hemorrhage-induced arterial narrowing
AU Vollmer, Dennis G.; Hongo, Kazuhiro; Kassell, Neal F.; Ogawa, Hisayuki; Tsukahara, Tetsuya; Lehman, R. Michael
CS Sch. Med., Univ. Virginia, Charlottesville, VA, USA
SO Hum. Pathol. (1989), 20(4), 599-604
CODEN: HPCQA4; ISSN: 0046-8177
DT Journal
LA English

L56 ANSWER 41 OF 47 CA COPYRIGHT 2001 ACS
AN 109:1009 CA
TI Relationship between sex hormones and hemostatic factors in healthy middle-aged men
AU Bonithon-Kopp, Claire; Scarabin, Pierre Yves; Bara, Lucienne; Castanier, Michel; Jacqueson, Alain; Roger, Marc
CS Hop. Broussais, Paris, 75674, Fr.
SO Atherosclerosis (Shannon, Irel.) (1988), 71(1), 71-6
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

L56 ANSWER 42 OF 47 CA COPYRIGHT 2001 ACS
AN 95:4832 CA
TI Studies on the clinical significance of antithrombin III with special reference to its metabolism
AU Okuda, Seisuke
CS Second Dep. Intern. Med., Kyoto Prefect. Univ. Med., Kyoto, Japan
SO Kyoto-furitsu Ika Daigaku Zasshi (1981), 90(3), 247-64
CODEN: KFIZAO
DT Journal
LA Japanese

L56 ANSWER 43 OF 47 CA COPYRIGHT 2001 ACS
AN 93:218538 CA
TI Biosynthesis of antithrombin III (AT III) in rat
AU Okuda, Seisuke; Okajima, Yasushi; Kawamura, Tsunehiro; Urano, Sumio; Nishizawa, Akihiko; Kitani, Teruo; Watada, Mitsuro; Nakagawa, Masao; Ijichi, Hamao
CS 2nd Dep. Med., Kyoto Prefect. Univ. Med., Kyoto, Japan
SO Ketsueki to Myakkan (1980), 11(1), 121-4
CODEN: KTMYA3; ISSN: 0386-9717
DT Journal

LA Japanese

L56 ANSWER 44 OF 47 CA COPYRIGHT 2001 ACS
AN 93:203085 CA
TI Hemostatic variables in vegetarians and non-vegetarians
AU Haines, A. P.; Chakrabarti, R.; Fisher, Diana; Meade, T. W.; North, W. R. S.; Stirling, Yvonne
CS MRC Epidemiol. Med. Care Unit, Northwick Park Hosp., Harrow/Middlesex, HA1 3UJ, Engl.
SO Thromb. Res. (1980), 19(1-2), 139-48
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L56 ANSWER 45 OF 47 CA COPYRIGHT 2001 ACS
AN 92:196003 CA
TI Role of antithrombin III in experimental and clinical states of increased thrombin generation in the blood
AU Pastorova, V. E.
CS USSR
SO Vestn. Mosk. Univ., Ser. 16: Biol. (1980), (1), 18-24
CODEN: VMUBDF
DT Journal
LA Russian

L56 ANSWER 46 OF 47 CA COPYRIGHT 2001 ACS
AN 91:104211 CA
TI The use of chromogenic substrates for the determination of kallikrein and other serine proteases in plasma and synovial fluid in man
AU Lewis, David H.; Bengtsson, Maj Britt; Liljedahl, Sten Otto; Larsson, Joergen
CS Clin. Res. Cent., Univ. Hosp., Linkoeping, S-581 85, Swed.
SO Adv. Biosci. (1979), 17(Curr. Concepts Kinin Res.), 163-71
CODEN: AVBIB9; ISSN: 0065-3446
DT Journal
LA English

L56 ANSWER 47 OF 47 CA COPYRIGHT 2001 ACS
AN 87:36920 CA
TI Content of antithrombin III, fibrinogen and its degradation products, soluble fibrin in the blood and components of the fibrinolytic system in the urine in patients with ischemic heart disease
AU Panchenko, V. M.; Andreenko, G. V.; Podorol'skaya, A. V.; Bazgadze, V. M.
CS Mosk. Gos. Univ., Moscow, USSR
SO Klin. Med. (Moscow) (1977), 55(1), 25-31
CODEN: KLMIAZ
DT Journal
LA Russian

=> d l56 31 24 16 14 all

L56 ANSWER 31 OF 47 CA COPYRIGHT 2001 ACS
AN 125:158640 CA
TI New clinical uses for human-derived antithrombin III
IN Okajima, Kenji; Taoka, Juji
PA Green Cross Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese

IC ICM A61K038-55
ICS A61K038-55
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08169845	A2	19960702	JP 1995-7731	19950120

PRAI JP 1994-5131 19940121
JP 1994-50813 19940322
JP 1994-256508 19941021

AB Human-derived antithrombin III is claimed for prevention and treatment of motor functional disturbance, tissue injury, spinal injury, and spinal **ischemia**. The antithrombin III can be formulated into any dosage forms. Thus, i.v. injections contg. human-derived antithrombin III were prepd., and their efficacy were tested in rat models.
ST antithrombin III spinal injury **ischemia**; New antithrombin III
IT Animal tissue
Spinal cord
(disease, injury, new clin. uses for human-derived antithrombin III)
IT Spinal cord
(disease, **ischemia**, new clin. uses for human-derived antithrombin III)
IT Pharmaceutical dosage forms
(injections, i.v., new clin. uses for human-derived antithrombin III)
IT Nerve, disease
(motor, new clin. uses for human-derived antithrombin III)
IT **9000-94-6**, Antithrombin III
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new clin. uses for human-derived antithrombin III)

L56 ANSWER 24 OF 47 CA COPYRIGHT 2001 ACS
AN 127:326191 CA
TI Antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion
AU Ostrovsky, Lena; Woodman, Richard C.; Payne, Derrice; Teoh, Diane; Kubes, Paul
CS Department of Physiology and Biophysics, University of Calgary, Calgary, AB, T2N 4N1, Can.
SO Circulation (1997), 96(7), 2302-2310
CODEN: CIRCAZ; ISSN: 0009-7322
PB American Heart Association
DT Journal
LA English
CC 1-7 (Pharmacology)
Section cross-reference(s): 15
AB P-selectin has recently been shown to be essential for leukocyte rolling after the reperfusion of ischemic mesentery. However, the mediators responsible for neutrophil rolling in ischemic microvessels remain entirely unclear. Intravital microscopy was used to examine leukocyte kinetics in a feline mesentery **ischemia**/reperfusion model. Sixty minutes of **ischemia** followed by reperfusion caused a profound increase in leukocyte rolling and adhesion. Pretreatment with the endogenous antithrombotic agent antithrombin III (ATIII) infused as a bolus (250 U/kg) reduced neutrophil rolling and adhesion to preischemic levels during reperfusion. No effect was seen with heat-inactive ATIII. Importantly, ATIII posttreatment also significantly reduced neutrophil rolling and adhesion during reperfusion, suggesting that ATIII can reverse the leukocyte recruitment response induced by **ischemia**/reperfusion. Vascular permeability was also reduced by 50% after ATIII administration. To det. whether ATIII could reverse thrombin-induced rolling directly, neutrophil rolling was performed on human endothelium in

flow chambers. Indeed, thrombin-induced rolling, but not histamine-induced rolling, could be rapidly reversed with ATIII on endothelium, suggesting that ATIII affects thrombin rather than directly affecting neutrophils or the endothelium. This study demonstrates for the first time that thrombin plays an important role in **ischemia**-induced leukocyte rolling and adhesion and that ATIII can be used therapeutically postreperfusion to attenuate the leukocyte recruitment response in inflammation without the nonspecific effects assocd. with anti-adhesion mol. therapy.

ST antithrombin III leukocyte recruitment **ischemia** reperfusion

IT Blood flow
Inflammation
Ischemia
Leukocyte
Leukocyte rolling
Microvessel
Neutrophil
Neutrophil adhesion
Reperfusion injury
Vascular endothelium
Vascular permeability
(antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion)

IT Peritoneal diseases
(mesenteric **ischemia**; antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion)

IT **Ischemia**
(mesenteric; antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion)

IT 9002-04-4, Thrombin
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion)

IT **9000-94-6**, Antithrombin
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antithrombin III prevents and rapidly reverses leukocyte recruitment in **ischemia**/reperfusion)

L56 ANSWER 16 OF 47 CA COPYRIGHT 2001 ACS

AN 130:176992 CA

TI The anti-inflammatory properties of antithrombin III: new therapeutic implications

AU Okajima, Kenji; Uchiba, Mitsuhiro

CS Department of Laboratory Medicine, Kumamoto University School of Medicine, Kumamoto, 860, Japan

SO Semin. Thromb. Hemostasis (1998), 24(1), 27-32
CODEN: STHMBV; ISSN: 0094-6176

PB Thieme Medical Publishers, Inc.

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

AB A review with 35 refs. Antithrombin III (AT III) supplementation has proven to be effective in the treatment of disseminated intravascular coagulation. Administration of AT III is also useful for prevention of organ failure in animals challenged with endotoxin or bacteria and it increases the survival rate of such animals. Since inhibition of coagulation abnormalities failed to prevent organ failure in animals given bacteria, AT III may exert a therapeutic effect independent of its

anticoagulant effect. This therapeutic mechanism of AT III has been explored using an animal model of septicemia. AT III prevented pulmonary vascular injury by inhibiting leukocyte activation in rats given endotoxin. This effect is mediated by the promotion of endothelial release of prostacyclin which inhibits leukocyte activation. Interaction of AT III with heparin-like glycosaminoglycans (GAGs) on the endothelial cell surface appears to be important for this effect. Heparin inhibits these therapeutic effects of AT III by preventing AT III from interacting with the cell surface heparin-like GAGs. This activity of AT III may explain why AT III prevents organ failure as well as coagulation abnormalities in patients with sepsis. This antiinflammatory activity of AT III may be useful for the treatment of organ failure such as in **ischemia**/reperfusion-induced organ dysfunction, in which activated leukocytes play a crit. role.

ST review antiinflammatory antithrombin therapeutic

IT Anti-inflammatory drugs
(anti-inflammatory activity of antithrombin and therapeutic implications)

IT **9000-94-6**, Antithrombin
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory activity of antithrombin and therapeutic implications)

RE.CNT 35

RE

(1) Atalla, S; Transplantation 1985, V40, P584 CA
(2) Buller, H; Am J Med 1989, V87(Suppl 3B), P44S
(3) Clotta, F; Am J Pathol 1994, V144, P975
(4) Coalson, J; Circ Shock 1978, V5, P423 CA
(5) Eisenhut, T; Immunopharmacol 1993, V26, P259 CA
(6) Emerson, T; Am J Med 1989, V87(Suppl 3B), P27S
(7) Fourrier, F; Chest 1993, V194, P882
(8) Gordon, J; Br J Pharmacol 1983, V80, P179 CA
(9) Harada, N; The Immune Consequence of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches 1997, P625 CA
(10) Horie, S; Thromb Res 1990, V59, P895 CA
(11) Jaeschke, H; FASEB J 1990, V4, P3355 MEDLINE
(12) Jochum, M; Semin Hematol 1995, V32(Suppl 2), P19
(13) Kainoh, M; Biochem Pharmacol 1990, V39, P477 CA
(14) Kim, Y; Transplantation 1994, V58, P875 CA
(15) Kushimoto, S; Crit Care Med 1996, V24, P1908 MEDLINE
(16) Maria Riva, C; Am J Resp Cell Mol Biol 1990, V3, P301
(17) Okajima, K; Am J Hematol 1991, V36, P265 MEDLINE
(18) Okajima, K; Am J Hematol 1997, V54, P219 CA
(19) Okajima, K; Thromb Haemostas 1989, V61, P20 CA
(20) Rosenberg, R; Am J Med 1989, V87(Suppl 3B), P2S
(21) Spannagel, M; Thromb Res 1981, V61, P1
(22) St John, R; Chest 1993, V103, P932 MEDLINE
(23) Stephans, K; Am Rev Respir Dis 1988, V138, P1300
(24) Suzuki, S; Transplantation 1991, V52, P978
(25) Tateson, J; Prostaglandins 1977, V13, P389 CA
(26) Taylor, F; Blood 1991, V78, P364
(27) Taylor, F; Circ Shock 1988, V26, P227 CA
(28) Triantaphyllopoulos, D; Thromb Haemostas 1984, V51, P232 CA
(29) Uchiba, M; Am J Physiol 1996, V270, PL921 CA
(30) Uchiba, M; Thromb Res 1995, V80, P201 CA
(31) Uchiba, M; to be published in Thromb Res 1998
(32) Vinazzer, H; Semin Thromb Hemostas 1989, V15, P347 MEDLINE
(33) Walker, R; Adv Shock Res 1982, V7, P125 CA
(34) Weiss, S; Blood 1980, V55, P1020 CA
(35) Yamauchi, T; Biochem Biophys Res Commun 1989, V163, P1404 CA

L56 ANSWER 14 OF 47 CA COPYRIGHT 2001 ACS

AN 130:246619 CA
TI Treatment of severe head injury with ahylysantifarctum
AU Liu, Weiping; Zhang, Xiang; Yi, Shengyu; Gu, Jianwen; Song, Tao
CS Department of Neurosurgery, 4th Military Medical University Xijing Hospital, Xi'an, 710033, Peop. Rep. China
SO Disi Junyi Daxue Xuebao (1998), 19(5), 529-531
CODEN: DJDXEG; ISSN: 1000-2790
PB Disi Junyi Daxue Xuebao Bianjibu
DT Journal
LA Chinese
CC 1-8 (Pharmacology)
AB Ahylysantifarctum was an antithrombin enzyme extd. from the Pallas pit viper snake venom. Sixty-nine patients with severe head trauma were randomly allocated to receive ahylysantifarctum therapy, traditional therapy, and nimodipine therapy sep. to search a better treatment of early cerebral microcirculation disturbances. There were significantly increased blood viscosity, hematocrit, and fibrinogen levels after severe head trauma. The patients' CSF exhibited metabolic acidosis, pH was 7.31.+-.0.07, PCO2 was 6.36.+-.1.13 kPa, HCO3- was 21.97.+-..10 mmol/L; and the decrease of pH was related with the severity of the condition. There were significant decrease in the blood viscosity, hematocrit, fibrinogen levels in the ahylysantifarctum therapy group, P<0.05; and the CSF environment was improved, the pH raised to 7.39.+-.0.09, P< 0.05; PCO2 reduced to 5.59.+-.1.38 kPa, HCO3- increased to 24.09.+-.1.92 mmol/L, P< 0.01; and the intracranial pressure reduced and cerebral perfusion pressure raised in some extent, P< 0.01. The results suggest the Pallas pit viper snake venom antithrombin enzyme ahylysantifarctum therapy solves the problem of impairment of cerebral microcirculation and **ischemia** after severe trauma, thus inducing beneficial effects in treatment of head injury.
ST ahylysantifarctum antithrombotic head trauma; antithrombin head trauma **ischemia**
IT Snake venoms
(Pallas pit viper; treatment of severe head injury with antithrombin enzyme ahylysantifarctum)
IT Cerebral blood flow
(micro-; treatment of severe head injury with antithrombin enzyme ahylysantifarctum)
IT Head injury
(trauma; treatment of severe head injury with antithrombin enzyme ahylysantifarctum)
IT Anti-ischemic agents
Antithrombotics
Cerebral **ischemia**
(treatment of severe head injury with antithrombin enzyme ahylysantifarctum)
IT **9000-94-6**, Antithrombin
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of severe head injury with antithrombin enzyme ahylysantifarctum)

=> d his

(FILE 'HOME' ENTERED AT 15:24:51 ON 12 APR 2001)

FILE 'REGISTRY' ENTERED AT 15:24:57 ON 12 APR 2001
L1 11 S NEUROSERPIN

```
L2            1 S PMSF
L3            1 S APMSF
L4            1 S L3
L5            5 S ANTIPAIN
L6          170 S ANTITHROMBIN
L7           11 S LEUPEPTIN
L8            9 S DICHLOROCOUMARIN
L9            2 S TLCK

     FILE 'REGISTRY' ENTERED AT 15:30:01 ON 12 APR 2001

     FILE 'CA' ENTERED AT 15:30:55 ON 12 APR 2001
L10          17 S L1
                E NEUROSERPIN
L11         728 S L2
L12          24 S L3
L13         343 S L5
L14        4326 S L6
L15         171 S L7
L16          16 S L8
L17         372 S L9
                E NEUROPATHY
L18        5490 S E3
                E EPILEPSY
L19       10805 S E3-E12
                E SEIZURE
L20       14562 S E3-E6
                E HYPOXIA
L21       24801 S E3
                E STROKE
L22       11880 S E3
L23           0 S L17 AND L18
L24           0 S L17 AND L19
L25           0 S L17 AND L20
L26           0 S L17 AND L21
L27           0 S L17 AND L22
L28           0 S L16 AND L18
L29       25960 S L18 OR L19 OR L20
L30           0 S L29 AND L16
L31           0 S L29 AND L15
L32           4 S L29 AND L14
L33           0 S L29 AND L13
L34           0 S L29 AND L12
L35          30 S L29 AND L11
L36           0 S L29 AND L10
L37         350 S L21 AND L22
L38       36331 S L21 OR L22
L39           4 S L38 AND L10
L40           2 S L38 AND L11
L41           0 S L38 AND L12
L42           1 S L38 AND L13
L43          46 S L38 AND L14
L44           1 S L38 AND L15
L45           0 S L38 AND L16
L46           0 S L38 AND L17
                E ISCHEMA
L47       40127 S E6
L48           3 S L47 AND L10
L49           0 S L47 AND L16
L50           3 S L47 AND L15
L51           3 S L47 AND L11
L52           0 S L47 AND L12
L53           1 S L47 AND L13
```

```
L54           52 S L47 AND L14
L55        28898 S HIS
L56           47 S L54 NOT L43

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   192.90     251.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -11.76     -11.76

STN INTERNATIONAL LOGOFF AT 16:08:56 ON 12 APR 2001
```